Treatment of Giardiasis

Article (PDF Available)inClinical Microbiology Reviews 14(1):114-28 · February 2001with327 Reads
DOI: 10.1128/CMR.14.1.114-128.2001 · Source: PubMed
Abstract
Giardia lamblia is both the most common intestinal parasite in the United States and a frequent cause of diarrheal illness throughout the world. In spite of its recognition as an important human pathogen, there have been relatively few agents used in therapy. This paper discusses each class of drugs used in treatment, along with their mechanism of action, in vitro and clinical efficacy, and side effects and contraindications. Recommendations are made for the preferred treatment in different clinical situations. The greatest clinical experience is with the nitroimidazole drugs, i.e., metronidazole, tinidazole, and ornidazole, which are highly effective. A 5- to 7-day course of metronidazole can be expected to cure over 90% of individuals, and a single dose of tinidazole or ornidazole will cure a similar number. Quinacrine, which is no longer produced in the United States, has excellent efficacy but may be poorly tolerated, especially in children. Furazolidone is an effective alternative but must be administered four times a day for 7 to 10 days. Paromomycin may be used during early pregnancy, because it is not systematically absorbed, but it is not always effective. Patients who have resistant infection can usually be cured by a prolonged course of treatment with a combination of a nitroimidazole with quinacrine.

Figures

CLINICAL MICROBIOLOGY REVIEWS,
0893-8512/01/$04.000 DOI: 10.1128/CMR.14.1.114–128.2001
Jan. 2001, p. 114–128 Vol. 14, No. 1
Copyright © 2001, American Society for Microbiology. All Rights Reserved.
Treatment of Giardiasis
TIMOTHY B. GARDNER AND DAVID R. HILL*
Division of Infectious Diseases, University of Connecticut Health Center, Farmington, Connecticut
INTRODUCTION .......................................................................................................................................................114
BACKGROUND ..........................................................................................................................................................114
THERAPY OF GIARDIASIS.....................................................................................................................................116
Classes of Agents and Clinical Properties ..........................................................................................................116
Nitroimidazoles ...................................................................................................................................................116
Quinacrine ...........................................................................................................................................................118
Furazolidone ........................................................................................................................................................119
Benzimidazoles ....................................................................................................................................................120
Paromomycin .......................................................................................................................................................121
Bacitracin zinc.....................................................................................................................................................121
Emerging and experimental therapeutics........................................................................................................121
Special Situations ...................................................................................................................................................122
Pregnancy and lactation ....................................................................................................................................122
Asymptomatic infection......................................................................................................................................122
Resistance and relapse.......................................................................................................................................123
RECOMMENDATIONS ............................................................................................................................................123
ACKNOWLEDGMENT..............................................................................................................................................124
REFERENCES ............................................................................................................................................................124
INTRODUCTION
Giardia lamblia, also called Giardia duodenalis or Giardia
intestinalis, is a protozoan parasite of the small intestine that
causes extensive morbidity worldwide. It was first described in
the late 17th century by the Dutch microscopist Antonie van
Leeuwenhoek (62), and research into its epidemiology, patho-
genesis, and treatment has intensified since G. lamblia water-
borne outbreaks were reported in Europe and the United
States during the 1960s and 1970s (53, 81, 123, 128, 174).
Giardia infects approximately 2% of the adults and 6 to 8% of
the children in developed countries worldwide and is currently
responsible for the largest number of waterborne outbreaks of
diarrhea in the United States (54, 139).
Despite the recognition of G. lamblia clinical illness for the
last 40 years, the nearly 5,000 people hospitalized with giardi-
asis annually in the United States (149), and the millions in-
fected worldwide, there have been few reviews of therapy for
this infection and no definitive treatment protocols have been
published (58, 113, 150, 165, 261). In addition, only a handful
of agents have been used in therapy, and the agents which are
available may have adverse effects or be contraindicated in
certain clinical situations. Also, resistance may play a role in
some infections. This paper will review the agents currently
used for the treatment of giardiasis. The history, mechanism of
action, in vitro and clinical studies, and adverse effects are
detailed for each drug class. In addition, special clinical situa-
tions are discussed and recommendations for therapy are made.
BACKGROUND
The life cycle of G. lamblia has two forms: the trophozoite
(Fig. 1) and the cyst. The cyst is the infectious form and is
ingested in contaminated water or food or directly from fecal-
oral contact. As few as 10 cysts may establish infection (206).
After ingestion, excystation occurs. Excystation is thought to
be initiated by contact with acidic gastric contents, followed by
a highly coordinated sequence of events leading to the release
of one or two trophozoites (27, 109, 210). A parasite-derived
protease may be activated during the excystation process (252).
The trophozoite infects the duodenum and upper intestine,
which have a favorable alkaline pH, and gives rise to the
clinical sequelae. As trophozoites pass through the small in-
testine to the colon, encystation occurs. Encystation can be
initiated in vitro by culture of parasites in a reduced concen-
tration of bile salts and cholesterol followed by culture in an
increased concentration of bile at an alkaline pH (156). Cyst
wall proteins are then transcribed, secreted into encystment-
specific vesicles, and transported to the newly forming cell wall
over 14 to 16 h (75).
The wide variety of clinical presentations, from severe dis-
ease to an asymptomatic carrier state, makes the definitive
determination of pathogenesis difficult. However, several the-
ories have been put forward (83, 115). Some of the most likely
include the ability of the protozoan to cause direct damage to
the intestinal mucosa via adherence with the disk, disacchari-
dase enzyme reduction following brush border damage, the
release from Giardia of cytopathic substances such as thiol
proteinases and lectins, and the stimulation of a host immune
response with release of cytokines and mucosal inflammation
(41, 48, 61, 78, 83, 106, 110, 157, 259). Additionally, it is likely
that there are genetic differences between Giardia isolates
which may confer virulence (115, 173, 182, 190). The surface of
Giardia may also undergo antigenic variation in the human
* Corresponding author. Mailing address: Division of Infectious
Diseases, University of Connecticut Health Center, Farmington, CT
06030-3212. Phone: (860) 679-4700. Fax: (860) 679-4701. E-mail: dhill
@exchange.uchc.edu.
114
host and thus evade immune detection (181). Given these
multiple potential mechanisms, a multifactoral process is
likely.
G. lamblia is found primarily in mammals including humans,
cats, dogs, beavers, and cattle (40, 74, 77, 257). Transmission of
the G. lamblia cyst to humans occurs most commonly following
ingestion of contaminated water (139). Transmission via sur-
face water is facilitated by the relative resistance of the cyst to
chlorination and its ability to survive in cold water for weeks
(59, 122). Transmission by food (22, 152, 187), by direct fecal-
oral contact among children in day care (28, 224, 237) or in
developing-world settings (96, 159), and by sexual practices
which include oral-anal contact (168) represent other common
modes of transmission (113). G. lamblia is also seen as a cause
of prolonged diarrhea in travelers (37, 66, 125, 136, 205; N.
Fiumara, Letter, N. Engl. J. Med. 288:1410–1411, 1973).
Worldwide, the majority of patients infected with G. lamblia
are asymptomatic. However, typical clinical symptoms of giar-
diasis usually begin 1 to 3 weeks after ingestion of cysts and are
marked by diarrhea, malaise, flatulence, greasy stools, and
abdominal cramps (113, 256). Other symptoms commonly in-
clude bloating, weight loss (174), and anorexia. Vomiting and
fever are less common, and blood- or mucus-tinged feces are
rare. Illness can last several months if untreated and can be
characterized by continued exacerbations of diarrheal symp-
toms. With chronic illness, malabsorption of fat, lactose, vita-
min A, and vitamin B
12
are reported, and failure of children to
thrive has been noted (86, 112, 149, 184, 227).
Giardiasis should be considered in the differential diagnosis
of many diarrheal syndromes. A careful history, which notes
any risk factors such as recent travel, wilderness exposure, or
situations involving poor fecal-oral hygiene, and a physical
examination are essential. Infection with G. lamblia can often
be distinguished from bacterial and viral infections because of
the longer duration of illness, 7 to 10 days by the time of
presentation, and the presence of weight loss (113). Parasitic
diarrhea with Cryptosporidium or Cyclospora can have similar
features in the immunologically normal host and would need to
be distinguished by specific diagnostic testing (50, 99).
Several methods exist for detection of the parasite. Demon-
stration of trophozoites or cysts in the stool, called the ova and
parasite (O&P) examination, is the traditional means of diag-
nosis (167). One stool sample will allow the detection of 60 to
80% of infections, 2 stool samples will allow the detection of 80
to 90%, and three stool samples will allow the detection of over
90% (97, 111). However, in some instances, because of inter-
mittent or low levels of shedding, it is necessary to examine
more than three stool samples. The desire for more sensitive
and specific, as well as faster and reproducible, diagnostic
testing has led to the development of immunoassays. Fecal
FIG. 1. Ventral surface of a Giardia lamblia trophozoite imaged by scanning electron microscopy. It demonstrates the disk and flagella. A
second trophozoite is seen behind it. Magnification, 8,100. Photo courtesy of David Dorward, Rocky Mountain Laboratory, National Institutes
of Health, Hamilton, Mont.
V
OL. 14, 2001 TREATMENT OF GIARDIASIS 115
antigen detection using enzyme-linked immunosorbent assays,
nonenzymatic immunoassays, or fluorescein-tagged monoclo-
nal antibodies can be superior diagnostic methods to the O&P
examination (7, 89, 90, 161, 262). It is particularly helpful in
assessing cure or in screening for Giardia infection. However,
when other parasites are in the differential diagnosis, a stool
sample for O&P examination should still be ordered. In the
unusual patient for whom a diagnosis cannot be made by O&P
examination of stool, endoscopy with duodenal fluid sampling
and biopsy may be performed (82, 113, 185, 256). An instance
in which this may be helpful is the human immunodeficiency
virus-infected patient with diarrhea, whose illness has multiple
potential etiologies. Culture and sensitivity testing is available
only in research settings (120, 138). DNA probes have been
generally limited to detection of parasites in water samples
(134, 158), and serologic testing is most useful in epidemiologic
surveys (118, 119, 170). Figure 2 outlines an approach to the
diagnosis and management of suspected cases of giardiasis and
is discussed further below (see “Recommendations”).
THERAPY OF GIARDIASIS
When evaluating the clinical efficacy of agents used against
Giardia, it is difficult to compare studies. They vary as to entry
methodology (whether randomization was done and if treat-
ment was blinded or open), population studied (children,
adults, symptomatic and/or asymptomatic patients), outcome
measures (clinical efficacy and/or stool negativity), and dura-
tion of follow-up. Nevertheless, conclusions may be drawn
from the studies when viewed as a whole, and statements can
be made about the relative efficacy of the agents.
Classes of Agents and Clinical Properties
Nitroimidazoles. The nitroimidazoles class of agents used to
treat G. lamblia infection includes metronidazole, tinidazole,
ornidazole, and secnidazole. This class was discovered in 1955
and was found to be highly effective against several protozoan
infections (240). Metronidazole [1-(-hydroxyethyl)-2-methyl-
5-nitroimidazole; Flagyl] was determined to be therapeutic
against Trichomonas vaginalis and Entamoeba histolytica fol-
lowing its discovery in the late 1950s (67), and in 1962 Darbon
et al. reported that it could be used to treat giardiasis (57).
Since this discovery, metronidazole and other nitroimidazoles
have been used by clinicians as the mainstay of therapy of
giardiasis.
Of the nitroimidazoles, the mechanism of killing of Giardia
by metronidazole has been the most thoroughly studied. Met-
ronidazole utilizes the anaerobic metabolic pathways present
in Giardia. The drug enters the trophozoite, and once it is
FIG. 2. Outline of the diagnosis and management of suspected cases of giardiasis.
116 GARDNER AND HILL C
LIN.MICROBIOL.REV.
within the cell, electron transport protein ferredoxins from the
parasite donate electrons to the nitro group of the drug (223,
238, 244). The drug becomes “activated” by reduction of this
nitro group (223, 238, 240), and a gradient favoring the intra-
cellular transport of metronidazole is established by this re-
duction reaction. Reduced metronidazole serves as a terminal
electron acceptor which binds covalently to DNA macromole-
cules (72, 177). This results in DNA damage in the form of loss
of helical structure, impaired template function, and strand
breakage, with subsequent trophozoite death (95). In addition
to this effect, metronidazole inhibits trophozoite respiration
(81, 189). The reductive activation of metronidazole may also
lead to toxic radicals, which react with essential cellular com-
ponents (244). Trophozoites within cysts may be less affected
by nitroimidazoles, possibly because of poor penetration of
drug through the cyst wall (236). Resistance to metronidazole
has been induced in vitro (29). It correlates with decreased
activity of parasite pyruvate:ferredoxin oxidoreductase, which
is required for reductive activation of nitroimidazoles (239,
247).
Metronidazole is quickly and completely absorbed after oral
administration and penetrates body tissues and secretions such
as saliva, breast milk, semen, and vaginal secretions (240). The
drug is metabolized mainly in the liver and is excreted in the
urine (147).
In vitro assays for nitroimidazole drug susceptibility have
been performed with G. lamblia since 1980 (112). Using mi-
croscopic evaluation of parasite morphology and mobility,
Jokipii and Jokipii first demonstrated that metronidazole and
tinidazole were effective (129). Subsequently, morphology (13,
166, 175), growth inhibition (56, 69, 94, 116, 160, 225), [
3
H]thy-
midine incorporation (32, 117, 164), serum killing (114), vital-
dye exclusion (114, 235), inhibition of adherence (21, 55, 79,
166, 192), metabolic (228), and colorimetric (133) assays have
been employed to measure the in vitro response of the drug to
many therapeutic agents. However, as indicated by the variety
of assays used, there is no standard for in vitro testing, making
it difficult to compare results and apply in vitro findings to the
clinical setting.
Of the nitroimidazoles, tinidazole and metronidazole have
consistently demonstrated the greatest in vitro activity; tinida-
zole possesses a slight advantage (30, 32, 55, 101). More highly
substituted nitroimidazoles, such as miconazole, clotrimazole,
itraconazole, and ketoconazole, were developed for their an-
tifungal activity and are not effective agents against G. lamblia
(55). Sensitivity to nitroimidazoles can vary depending on the
stocks and clones of G. lamblia used in testing (29, 31, 79, 160).
In the United States, metronidazole is the only member of
the nitroimidazole class available to treat giardiasis; it is also
the most common drug used for treatment worldwide. In spite
of its widespread and accepted use against Giardia, the U.S.
Food and Drug Administration has never approved it for this
indication. Clinical trials have employed dosing two and three
times daily (usually 250 mg/dose) for 5 to 10 days and short-
course (1 to 3 days), daily single-dose therapy (2.0 or 2.4 g/
dose) (261). In the 5- to 10-day schedules the efficacy ranges
from 60 to 100% in adult and pediatric patients, with a median
efficacy in both groups of 92% (Table 1) (20, 49, 68, 91, 92, 100,
127, 132, 135, 150, 151, 191, 201, 202, 232, 256). In general, this
schedule is well tolerated, with most side effects involving gas-
trointestinal upset and metallic taste (Table 2).
The single-dose, short-course treatments (one high dose
given daily) were designed to improve compliance without
sacrificing efficacy. They have been used in both adults and
children. These regimens are generally less efficacious, partic-
ularly if only one dose of metronidazole is given. The efficacy
of single-dose therapy ranges from 36 to 60% if the drug is
given for 1 day (16, 93, 127, 130, 220, 229) and rises to 67 to
80% if the drug is given for 2 days (Table 1) (127, 130, 146; E.
Green, D. M. Lynch, J. A. McFadzean, and I. M. Pugh, Letter,
Br. Med. J. 2:411–412, 1974). Continuing single-dose treat-
ment for 3 days increases efficacy to the range seen with lower-
dose, longer-course therapies (229; Green et al., Letter). The
high-dose regimens may also carry more side effects (127).
Children have been included in many of the trials of both
long- and short-course therapy, with outcomes similar to those
in adults and 80 to 100% efficacy (median, 94%) in the 5- to
10-day regimens (91, 100, 132, 135, 186, 201, 232; A. Rastegar-
Lari and A. Salek-Moghaddam, Letter, J. Trop. Pediatr. 42:
184–185, 1996). Although metronidazole does not come in a
standard liquid form, a suspension can be prepared by thor-
oughly crushing metronidazole tablets, using a drop of glycerin
as a lubricant, and suspending the mixture in Cherry Syrup NF
(150).
The most common side effects of metronidazole treatment
include headache, vertigo, nausea, and a metallic taste in the
mouth (Table 2). Nausea occurs in 5 to 15% of patients given
standard multiday courses (135, 151). In addition, pancreatitis,
central nervous system toxicity at high doses (144, 212), and
transient, reversible neutropenia have been attributed to met-
ronidazole (147). Patients should be warned to avoid alcohol
while taking metronidazole. The inhibition of aldehyde dehy-
drogenase by metronidazole can cause severe vomiting, flush-
ing, headache, and gastrointestinal pain following alcohol in-
gestion.
Metronidazole is mutagenic in bacteria and carcinogenic in
mice and rats at high doses over long periods (34, 153, 240,
251). However, mutagenicity has never been documented in
humans, suggesting that the use of metronidazole is safe in this
regard (23, 78, 98, 212). This may, however, mitigate against
the short-course high-dose regimens in children.
The finding of therapeutic efficacy with metronidazole
spurred investigators to develop and test other nitroimidazole
derivatives. The other agents, tinidazole, ornidazole, and sec-
nidazole, each have longer half-lives, making them suitable for
single daily-dose therapies (217). One dose of tinidazole
(Fasigyn) was successfully used in 1971 in a group of Swedish
students who acquired giardiasis during a visit to Russia (11).
This single, 2-g dose (or equivalent in children) has consis-
tently proven to have a clinical efficacy of 80 to 100% with a
median efficacy of 92% (Table 1) (16, 126, 130, 131, 146, 151,
193, 222, 229, 261; Z. Farid, N. A. El Masry, W. F. Miner, and
A. Hassan, Letter, Lancet ii:721, 1974; T. Pettersson, Letter,
Br. Med. J. 1:395, 1975) and is far superior to metronidazole
when single-dose regimens are directly compared (93, 130, 229,
261). There is also improved compliance with this dosing
schedule. The recommended dosing for pediatric populations
is usually 50 mg/kg for a single dose (Table 2) (82, 193, 232,
256), and the drug is available in a liquid suspension.
VOL. 14, 2001 TREATMENT OF GIARDIASIS 117
Adverse effects reported with tinidazole are not as common
as with metronidazole but do include bitter taste, vertigo, and
gastrointestinal upset (Table 2) (130, 131; Pettersson, Letter).
Tinidazole is not available in the United States, but travel
health providers recommend that some travelers, particularly
long-term travelers or overland trekkers in Asia, purchase the
drug upon arrival at their country of destination and take it in
the event of acquiring giardiasis (113).
Another nitroimidazole derivative which is also not available
in the United States is ornidazole. There have been fewer
studies with ornidazole, but it has excellent efficacy when given
over several days and efficacy similar to tinidazole (92 to 100%)
when given as a single dose (19, 131, 145, 220, 232, 261).
Single-dose ornidazole (40 mg/kg) has also been given to chil-
dren, with obvious benefits regarding compliance and cost (39,
186). In one study the drug was given intravenously and was
associated with increased side effects, making the investigators
reluctant to recommend routine use of this drug in children
until large-scale studies of recurrence, carcinogenicity and side
effects are completed (39).
Secnidazole, a long-acting 5-nitroimidazole derivative, has
been used but is not available in the United States. Similar to
tinidazole and ornidazole, secnidazole is usually given as a
single dose. The most common regimen is2ginadults and 30
mg/kg in children (95). Clinical studies demonstrate efficacy
rates of over 85% with the single dose in adults (49; R. Baqai,
H. Qureshi, and S. J. Zuberi; Letter, J. Pak. Med. Assoc.
45:288, 1995), and in children, this dosing is as effective as a 7-
to 10-day course of metronidazole (100; Rastegar-Lari and
Salek-Moghaddam, Letter). The drug is rapidly and com-
pletely absorbed, has a half-life of 17 to 29 hours, and is
metabolized via oxidation in the liver (95). Adverse effects
have been reported, most notably gastrointestinal disturbance
(nausea, anorexia, and abdominal pain) and dizziness, but usu-
ally do not require discontinuation of the drug.
Quinacrine. Quinacrine (Atabrine) was first introduced as
an antimalarial agent in 1930, following the work of Kikuth,
and became the antimalarial of choice for allied troops in
World War II because of its greater availability and better
tolerance compared with quinine (240). After the war, it soon
became an important agent against G. lamblia, with a clinical
efficacy of 90% or more (20, 52, 105, 255). However, with a
U.S. market limited to the treatment of Giardia, the use of
quinacrine declined, and its production in the United States
was discontinued in 1992, although it may still be obtained
through alternative sources (Table 2).
The antiprotozoal mechanism of quinacrine is not fully elu-
cidated. The drug intercalates readily with G. lamblia DNA,
and it is this interaction which is thought to cause an inhibition
of nucleic acid synthesis (240). The differing relative quina-
crine uptake rate between human and G. lamblia cells may be
responsible for the selective toxicity of the drug (236). In vitro,
quinacrine reduces cyst viability and excystation rates (179,
189). Resistance has been induced in vitro, and in one study it
TABLE 1. Efficacy of anti-Giardia drugs in adult and pediatric infection
a
Drug Dose
b
Median efficacy (%)
c
Efficacy range (%)
Metronidazole 500–750 mg/day 5–10 days 88 60–95
2.0–2.4 g, single dose 48 36–60
2.0–2.4 g, q.d. 2 days 71 67–80
2.0–2.4 g, q.d. 3 days 93–100
15–22.5 mg/kg/day 5–10 days
d
94 80–100
Tinidazole 300 mg/day 7 days 87 74–100
1.0–2.0 g, single dose 92 86–100
50 mg/kg, single dose
d
91 80–96
Ornidazole 1.0–2.0 g, single dose 96–100
40–50 mg/kg, single dose
d
92–100
Secnidazole 2.0 g, single dose 86–100
30 mg/kg, 1 or 2 doses
d
88–100
Quinacrine 300 mg/day 5–7 days 95–100
6–8 mg/kg/day 5–10 days
d
92–95
Furazolidone 400 mg/day 7–10 days 80–85
8 mg/kg/day 7–10 days
d
92 81–96
Albendazole 200–800 mg/day 1–3 days 24–81
200–400 mg/day 5–7 days 94–100
Paromomycin 10–50 mg/kg/day or 1,500 mg/day 5–10 days 55–88
Bacitracin zinc 240,000 U/day 10 days 95
a
Efficacy is based on studies that may vary in design, entry methodology, or outcome measure. When separate pediatric populations were studied, they are designated.
See the text for references.
b
Doses are total daily amounts, which may or may not have been given in divided doses. Actual treatment recommendations are presented in Table 2. q.d., once
a day.
c
Median efficacy is given when the results of four or more studies are included.
d
Pediatric population only.
118 GARDNER AND HILL CLIN.MICROBIOL.REV.
was correlated with decreased uptake of the drug (246). Quin-
acrine is rapidly absorbed from the intestinal tract and is widely
distributed in body tissues.
Although results differ, depending on the in vitro sensitivity
testing assay used, metronidazole and furazolidone have been
shown to be slightly more potent than quinacrine (30, 32, 55,
94). However, in other studies the in vitro efficacies of quina-
crine and metronidazole are the same (21, 117, 164). Some of
this difference may be related to the greater variation in sen-
sitivity to quinacrine than to metronidazole or furazolidone
between clones of Giardia (31).
Clinically, quinacrine is very effective, with studies establish-
ing its efficacy over 5 to 10 days at about 95% (Table 1) (20,
135, 220, 255). Some researchers consider the drug to be the
most efficacious of any of the anti-Giardia therapeutics (256).
Dosing is usually 100 mg three times a day over 5 to 7 days for
adults and 6 mg/kg/day in three divided doses over 5 to 7 days
for children (Table 2) (150).
Side effects have precluded many clinicians from using quin-
acrine, particularly in children (Table 2). A bitter taste, along
with vomiting, has been reported in up to 28% of study par-
ticipants (20, 52), and led to a lower efficacy in children
younger than 5 years (52), probably due to low compliance.
Yellow/orange discoloration of the skin, sclerae, and urine
affects 4 to 5% of those taking quinacrine, beginning about 1
week after starting treatment, and can last up to 4 months after
discontinuation of therapy. Other common side effects include
nausea, vomiting, headache, and dizziness (254). Drug-induced
psychosis is uncommon, and exfoliative dermatitis and quina-
crine-induced retinopathy are rare (82). Quinacrine can exac-
erbate psoriasis, and in glucose-6-phosphate dehydrogenase
(G6PDH)-deficient individuals, it can precipitate hemolysis. It
is contraindicated in pregnancy due to a possible link with
spina bifida and renal agenesis. It has never been demon-
strated to be carcinogenic, even though it has a mechanism of
action of binding to DNA.
Furazolidone. Furazolidone (Furoxone) is one of the thou-
sands of nitrofuran compounds created since the class was
discovered in the 1940s (143). It is effective against many bac-
teria including Klebsiella spp., Clostridium spp., Escherichia
TABLE. 2. Recommended dosing and adverse effects of anti-Giardia drugs
Drug Adult dose
f
Pediatric dose Adverse effects
Metronidazole
a
250 mg t.i.d. 5–7 days 5 mg/kg t.i.d. 5–7 days Headache, vertigo, nausea, metallic taste,
urticaria
Disulfiram-like reaction with alcohol
ingestion
Rare: pancreatitis, central nervous system
toxicity, reversible neutropenia, peripheral
neutropathy, T-wave flattening with
prolonged use
Mutagenic/carcinogenic?
Tinidazole
b
2 g, single dose 50 mg/kg, single dose (max, 2 g) As for metronidazole
Ornidazole
c
2 g, single dose 40–50 mg/kg, single dose (max, 2 g) As for metronidazole
Quinacrine
c
100 mg t.i.d. 5–7 days 2 mg/kg t.i.d. 7 days Nausea and vomiting, dizziness, headache
Yellow/orange discoloration of skin and
mucous membranes
Rare: toxic psychosis
Furazolidone
d
100 mg q.i.d. 7–10 days 2 mg/kg q.i.d. 10 days Nausea, vomiting, diarrhea
Brown discoloration of urine; disulfiram-like
reaction with alcohol ingestion
Reacts unfavorably with MAO inhibitors
Mild hemolysis in G6PDH deficiency
Carcinogenic?
Paromomycin
a
500 mg t.i.d. 5–10 days 30 mg/kg/day in 3 doses 5–10 days Ototoxicity and nephrotoxicity with systemic
administration
Albendazole
a
400 mg q.d. 5 days 15 mg/kg/day 5–7 days (max, 400 mg) Anorexia, constipation
Rare: reversible neutropenia and elevated
liver function tests
Teratogenic?
Bacitracin zinc
e
120,000 U b.i.d. 10 days Not tested in children under 10 yr Nausea, vomiting, abdominal discomfort
Nephrotoxicity with systemic absorption
a
Not a U.S. Food and Drug Administration-approved indication.
b
Not available in the United States.
c
No longer produced in the United States. May be obtained from Panorama Pharmacy, Panorama City, Calif.
d
Available in a liquid formulation.
e
Not a U.S. Food and Drug Administration-approved indication. Information is based on only one study (14).
f
q.d., once a day; b.i.d., twice a day; t.i.d., three times a day; q.i.d., four times a day.
VOL. 14, 2001 TREATMENT OF GIARDIASIS 119
coli, Campylobacter spp., and Staphylococcus aureus. As early
as the 1950s, furazolidone was being used in the treatment of
giardiasis (253). It is approved for use in the United States and
remains an important therapeutic agent worldwide. Of the
common anti-Giardia therapeutics, it is the only one available
in a liquid suspension in the United States; therefore, its use
has been advocated in pediatric populations (150).
The mechanism of action of furazolidone against G. lamblia,
like many of the antiparasitics, is not completely explained.
The drug undergoes reductive activation in the G. lamblia
trophozoite, but, unlike metronidazole, reduction possibly oc-
curs via an NADH oxidase (38, 244). Its killing effect correlates
with the toxicity of reduced products, which can damage im-
portant cellular components including DNA. Resistance to
furazolidone may be correlated with decreased entry of drug
(246) or with increased levels of thiol-cycling enzymes, which
can defend against toxic radicals (249). The drug is readily
absorbed via the gastrointestinal tract and is metabolized rap-
idly in tissues, leading to low concentrations in serum and urine
(143).
In in vitro susceptibility testing, furazolidone performs com-
parably to metronidazole and has consistently demonstrated
the highest activity of the nonimidazoles (32, 55, 101); it is
more active than quinacrine (30).
Clinical studies using furazolidone are numerous and have
been completed with a wide range of subjects, doses, and
administration schedules. Although its efficacy has generally
been considered to be slightly lower than those of metronida-
zole and quinacrine, curative rates between 80 and 96% have
been reported for 7- to 10-day courses (Table 1) (20, 52, 91,
151, 178, 191, 201, 255). It is when the drug is given for only 5
days that efficacy falls off considerably (151, 178). It is given as
four doses per day in both adults (100 mg per dose) and
children (1.5 mg/kg) (Table 2). In the pediatric suspension, two
tablespoonfuls substitute for a 100-mg tablet.
About 10% of patients report gastrointestinal symptoms
such as nausea, vomiting, and diarrhea (Table 2) (150, 256).
Other adverse effects can include a brown discoloration of the
urine; hemolysis can occur in G6PDH-deficient patients. The
drug has a monoamine oxidase (MAO) inhibitory effect and
should never be given concurrently to individuals already tak-
ing MAO inhibitors. There have been rare reports of disul-
firam-like reactions when it is taken with alcohol (164b). A
furazolidone-induced manic episode in a patient infected with
human immunodeficiency virus has been reported (73). Fura-
zolidone is also contraindicated in infants younger than 1
month of age, who could develop hemolytic anemia because of
their normally unstable glutathione. Finally, the drug is muta-
genic in bacteria and has been demonstrated to cause mam-
mary tumors in rats and pulmonary tumors in mice when given
in chronic high doses. However, the implication of this finding
for humans is not known and has not been adequately ad-
dressed (143, 164b, 236). When treating pediatric populations,
the advantages of its minimal adverse effects and the availabil-
ity of a liquid suspension must be weighed against the need for
frequent dosing over a 10-day treatment period.
Benzimidazoles. Two members of the benzimidazole class of
therapeutics, albendazole (Albenza) and mebendazole (Ver-
mox), have been used to treat G. lamblia infection (155). Clin-
ical and in vitro efficacy studies have produced different results
as to their effectiveness. However, a comparatively benign side
effect profile, combined with proven efficacy against many hel-
minths, renders them promising for treatment (208, 250).
The benzimidazoles exert their toxic effect on Giardia in part
by binding to the G. lamblia β-tubulin cytoskeleton (71, 175,
209). This binding causes both inhibition of cytoskeleton po-
lymerization and impaired glucose uptake (250). Although the
exact binding site on the cytoskeleton has not been deter-
mined, it is postulated that a benzimidazole-colchicine site
interaction may play a role (51, 166, 236). The benzimidazoles
are poorly absorbed from the gastrointestinal tract, although
this can be improved with the coingestion of a fatty meal. The
systemic effect of albendazole is due to its primary metabolite,
albendazole sulfoxide, which is rapidly formed in the liver
following absorption (3). Excretion by the kidneys is negligible.
In vitro susceptibility testing of G. lamblia to the benzimi-
dazoles is limited in comparison to the susceptibility of the
parasite to the nitroimidazoles or quinacrine. Nevertheless,
studies demonstrate a considerable in vitro effect (79, 175, 208,
209). One report showed that both albendazole and mebenda-
zole were 30- to 50-fold more active than metronidazole and 4-
to 40-fold more active than quinacrine in vitro (71). Another
demonstrated that the ability of albendazole to affect tropho-
zoite morphology, adherence, and viability was far greater than
that of metronidazole or tinidazole (166). However, their vari-
able clinical efficacy demonstrates the discordance between in
vitro testing and in vivo activity. Resistance to albendazole can
be induced in vitro (154) and correlates with changes in the
parasite cytoskeleton (243). Other benzimidazoles such as no-
codazole, oxfendazole, thiabendazole, and fenbendazole have
also demonstrated some in vitro efficacy (236).
Clinical trials have been limited to albendazole and meb-
endazole, with mixed results. Hall and Nahar reported equal
curative efficacy of albendazole and metronidazole in children
when albendazole was given for 5 days but not when it was
given in single or 3-day dosing (Table 1) (104). A decreased
efficacy of albendazole when given for 3 days or less was also
documented by Kollaritsch et al. in travelers with giardiasis
(137), by Pungpak et al. in children and adults (198), and by
Pengsaa et al. in children (193). Improved efficacy was seen in
other patients when the drug was given for 5 days (171, 207,
214) or 7 days (198). The exception to the need for longer
treatment courses was seen in one study in which a single dose
was administered (68). An albendazole-metronidazole combi-
nation was 100% effective in 20 patients with metronidazole-
resistant giardiasis who had failed three to five courses of
standard oral metronidazole therapy (44).
Treatment with mebendazole has resulted in widely diver-
gent clinical results. Al-Waili reported over 90% efficacy in two
studies in children (8, 9). However, other studies in both pe-
diatric and adult populations have not shown equal success but
instead have shown effectiveness in 80% (211) and in 60% or
less (39, 92, 132; L. di Martino, A. Nocerino, and M. Pettoello
Mantovani, Letter, Trans. R. Soc. Trop. Med. Hyg. 85:557–
558, 1991), as well as a failure to decrease the prevalence rates
of Giardia when mebendazole was used in mass treatment of
helminths (219). Because of this discrepancy, most interest has
focused on albendazole.
The dosage in adults is usually 400 mg per day for 5 days for
albendazole and 200 to 400 mg per day for 5 to 10 days for
120 GARDNER AND HILL CLIN.MICROBIOL.REV.
mebendazole (Table 2). The usual dosage in children is 15
mg/kg per day for 5 to 7 days. Both drugs are available in
suspension. One advantage of using albendazole in children is
its efficacy against many helminths, allowing effective treat-
ment of multiple intestinal parasites (207, 208). Another ad-
vantage is its relative lack of side effects. However, with short-
term use, it may cause gastrointestinal problems of anorexia
and constipation. Long-term, high-dose use of albendazole,
such as when it is used for larval cestode infections, has caused
reversible neutropenia and elevated hepatic enzyme levels (3,
155, 258). Albendazole is contraindicated in pregnancy, due to
possible teratogenicity (pregnancy category C), but animal
studies have shown no increase in carcinogenic incidence.
Paromomycin. Paromomycin (Humatin), a member of the
aminoglycoside family, was first isolated in 1956. It is indicated
for the treatment of Entamoeba histolytica and Trichomonas
and has been proposed as a treatment for G. lamblia in resis-
tant infections and during pregnancy (113, 140). Paromomycin
is poorly absorbed from the intestinal lumen; even large-dose
oral administrations achieve only minimal concentrations in
the blood and urine of patients with normal renal function
(140). Paromomycin inhibits G. lamblia protein synthesis by
interfering with the 50S and 30S ribosomal subunits (the par-
asite rRNA has an unusual size and sequence) and causing
misreading of mRNA codons (69).
In vitro susceptibility testing demonstrates that paromomy-
cin has activity against G. lamblia, but the activity is generally
lower than that of the nitroimidazoles, quinacrine, or furazo-
lidone (30, 101). However, because of poor intestinal absorp-
tion, it compensates for its low antiprotozoal activity by achiev-
ing high levels in the gut. In a rat model, the drug showed
efficacy (15).
Clinical studies are limited, and therapeutic efficacy ranges
from 55 to nearly 90% (Table 1) (47, 63, 140, 191, 218). The
usual dose is 500 mg three times per day for 10 days in adults
and 25 to 30 mg/kg/day (divided into three doses) in children
(Table 2).
As with other aminoglycosides, if absorbed systemically
paromomycin can cause ototoxicity and nephrotoxicity. How-
ever, it may be less ototoxic than other aminoglycosides (142),
and with limited systemic absorption, toxicity should not be a
concern in persons with normal kidneys. However, it should be
used with caution in those with impaired renal function.
Bacitracin zinc. The search for alternative, effective anti-
Giardia therapeutics has led investigators to consider bacitra-
cin. Bacitracin was first isolated in 1945 from a strain of Ba-
cillus and was used systemically against severe staphylococcal
infections until 1960, when its toxicity and the availability of
other antibiotics restricted it to mainly topical use (141). Zinc
was added to the bacitracin complex to promote stability. Bac-
itracin exerts its effect in bacteria by interfering with a dephos-
phorylation step in cell membrane synthesis. Following dem-
onstrated in vitro effectiveness against E. histolytica and
Trichomonas, bacitracin zinc was tested against Giardia in vitro
and found to be active (12, 13).
A clinical trial by Andrews et al. used twice-daily dosing over
10 days and compared the effectiveness of 120,000 U of baci-
tracin zinc, 120,000 U of bacitracin, 120,000 U of neomycin,
and 60,000 U of bacitracin zinc in combination with 60,000 U
of neomycin (14). Cure rates of 95% for bacitracin zinc, 88%
for either bacitracin or the bacitracin zinc-neomycin combina-
tion, and 86% for neomycin were demonstrated. Adverse ef-
fects were limited to a small number of patients who experi-
enced diarrhea, abdominal discomfort, constipation, and
nausea. Children younger than 10 years were excluded from
the study.
The disadvantages of using bacitracin zinc include a poten-
tial for nephrotoxicity with prolonged oral dosing and gastro-
intestinal disturbance. Furthermore, compliance can be af-
fected by the 10-day dosing period, and the formulations used
by Andrews in their study are not readily available. Although
bacitracin zinc is promising, more investigation is needed be-
fore it can gain wide acceptance as an agent against G. lamblia.
Emerging and experimental therapeutics. A wide variety of
chemotherapeutic agents including rifampin, bithionol, dichlo-
rophene, hexachlorophene, pyrimethamine, sodium fusidate,
chloroquine, and mefloquine have demonstrated in vitro activ-
ity against Giardia (81, 84, 233). Lipophilic tetracyclines, such
as doxycycline, are highly active in vitro; however, their clinical
efficacy is limited, perhaps because of their rapid absorption
from the intestine (70). Certain pentamidine analogs, as well as
azithromycin, have in vitro activity comparable to that of met-
ronidazole (25, 33).
Nitazoxanide, a 5-nitrothiazole derivative with broad-spec-
trum activity against protozoa, helminths, and some bacteria
has shown limited efficacy in adults and children in Mexico
(71% [213] and 78% [211] effectiveness, respectively) and in a
few AIDS patients in Mali (64). It has been given in a dose of
100 to 500 mg twice daily for 3 to 7 days.
Studies using a rat model have demonstrated the efficacy of
ivermectin under specific conditions (260). Disulfiram, a zinc
finger-active compound used for the treatment of alcoholism in
humans, shows significant cure rates and decreased parasitic
burdens in a mouse model of giardiasis (180).
In an ethnobotanical survey of the anti-Giardia gastrointes-
tinal remedies employed by the Luo tribes of East Africa,
methanolic extracts of 21 of the 36 taxa studied were lethal to
or inhibited the growth of G. lamblia in vitro (124). Geranium
nivem extracts have also shown in vitro activity (45). The im-
munomodulatory herbal drug Pippali rasayana, often pre-
scribed for the treatment of worm infections and chronic dys-
entery in India, achieved a 98% cure of murine infection with
G. lamblia (6). Extracts of Piper longum fruit were effective in
a mouse model of infection (241).
Proposlina, a bee glue preparation, demonstrated a 60%
parasitologic cure rate 1 week after treatment was completed
among 48 adults in Cuba (172, 261). In a patient with metron-
idazole-resistant Giardia infection, the -adrenergic antagonist
DL-propranolol, given in a dose of 40 mg three times a day with
400 mg of metronidazole three times a day for 10 days, cleared
infection, demonstrating clinical efficacy in humans (197). In
vitro studies demonstrate that propranolol exerts its effect by
inhibiting the motility and growth of the protozoan, most prob-
ably due to the membrane-stabilizing activity of the drug (85).
However, further studies with
DL-propranolol and the related
compound
D-propranolol are needed before they can be rec-
ommended as anti-Giardia agents.
Immunoprophylactic strategies to prevent or treat giardiasis
have generally not been effective (87). Passive transfer of anti-
Giardia immune serum did not facilitate parasite clearance in
VOL. 14, 2001 TREATMENT OF GIARDIASIS 121
murine giardiasis (76, 242). Although patients with common
variable immunodeficiency do have symptomatic and pro-
longed infection with Giardia antiparasitic therapy is required
to control their infection (106, 216). Breast milk can be cyto-
toxic to Giardia via free fatty acids which are generated from
milk triglycerides by the action of a bile salt-stimulated lipase
(204). Also, breast feeding may confer some protection to
suckling infants (176, 183); however the approach of providing
enteral anti-Giardia antibody has not been studied.
Special Situations
Pregnancy and lactation. The management of symptomatic
G. lamblia infection during pregnancy is a challenge for the
clinician because no therapeutic agent combines optimal effi-
cacy and safety. Women who are asymptomatic, have mild
disease, or are in their first trimester should usually avoid being
treated. However, women in whom adequate hydration and
nutritional status cannot be maintained should be treated, even
in the first trimester.
Metronidazole, which rapidly enters the fetal circulation af-
ter absorption by the mother, has demonstrated mutagenicity
in bacteria and carcinogenicity in mice and rats (34, 36, 153,
240, 251). While this information raises concern about the use
of the drug during pregnancy, carcinogenicity has not been
demonstration in humans (23, 24, 78, 98, 212), nor has there
been teratogenicity in rodents (164a). Metronidazole has been
used extensively during pregnancy (pregnancy category B), pri-
marily for therapy of trichomoniasis in 7- to 10-day courses
(42). The results regarding safety to the fetus are conflicting
(36, 42, 107, 212, 215, 218). One retrospective study of 1,469
women who took metronidazole in pregnancy, with 206 using
the drug in the first trimester, found no evidence of congenital
abnormality (26). However, the Collaborative Perinatal
Project, including over 50,000 mother-child pairs, demon-
strated that first-trimester exposure to metronidazole in 31
women showed a possible association with malformations
(107). A meta-analysis of seven studies, prospectively monitor-
ing 253 mother-infant pairs and retrospectively monitoring
1,083 pairs, found no increased risk of fetal malformation in
association with first-trimester use of metronidazole (42), with
one report estimating a relative risk of 0.92 for birth defects
(215). On balance, there may be a slightly increased risk when
using metronidazole during the first trimester, and thus its use
should be avoided during this period. High-dose (2.0 g),
short-course regimens should not be given during pregnancy.
Metronidazole is actively excreted in breast milk in concen-
trations similar to those in plasma. The American Academy of
Pediatrics (AAP) recommends giving a single 2-g dose in nurs-
ing mothers, followed by discontinuation of nursing for 12 to
24 h (10, 36). The AAP also recommends that mothers taking
tinidazole discontinue nursing for the same time period as
those taking metronidazole (10). However, metronidazole is
approved for use in children for therapy of amebiasis and is
used in children for therapy of anaerobic infections, so it would
seem that the small amount secreted in breast milk would not
be deleterious. Also, since single, high-dose regimens of met-
ronidazole have poor efficacy and would be expected to lead to
higher levels in breast milk, these findings favor traditional
treatment with lower doses over 5 to 7 days.
Paromomycin is generally considered safe because it is
poorly absorbed from the intestine and excreted almost 100%
unchanged in the feces. Therefore, little if any of the drug will
reach the fetus. However, it is not as effective as metronidazole
or quinacrine. In addition, no clinical trials have addressed the
effects of high serum concentrations of paromomycin during
pregnancy. Nevertheless, paromomycin has been used success-
fully to eradicate G. lamblia infection in the gravid patient and
is an important agent to consider during the first trimester,
when metronidazole should not be used (140, 218). Paromo-
mycin should also be safe in nursing mothers. A study in ewes
showed only a 0.018% drug recovery rate in breast milk for the
12 h following parenteral administration (36, 263). The AAP
does designate streptomycin and kanamycin, aminoglycoside
relatives of paromomycin, to be compatible with breast feeding
(10).
One expert on giardiasis has espoused quinacrine treatment
in pregnant patients due to its high cure rate (256). While the
drug is very effective, its slow excretion from the body and
proven teratogenicity in rats make it a suboptimal choice for
treatment in pregnancy. Although quinidine and quinine are
compatible with breast-feeding, no information regarding the
safety of quinacrine for the breast-fed child was available (10).
Furazolidone is not recommended for the pregnant patient.
Although it is efficacious, its has caused mammary tumors in
mice and mutations in bacteria, which should deter the physi-
cian from using it in this setting (164b). Its safety for breast-fed
children is not known. Albendazole is considered a pregnancy
category C agent, and has been teratogenic in rats and rabbits,
although there is little experience of its effects in pregnant
women.
Asymptomatic infection. On a global basis, most persons
infected with G. lamblia are asymptomatic or minimally symp-
tomatic. Treating asymptomatic patients, particularly children,
is controversial, and there are several factors to consider be-
fore initiating therapy. The setting of the infection plays a key
role in the decision. In areas where G. lamblia is endemic,
treatment may not be desirable because the children are likely
to become rapidly reinfected following treatment (96, 231). If
Giardia contributes to failure of growth and development (86,
163, 227), treatment, even though reinfection may occur, might
allow catch-up growth (103) and might be worth the cost and
effort. A drug such as albendazole, which would also treat
nematode infections, might be useful in these settings; how-
ever, the requirement for 5-day dosing would make it difficult
to complete therapy in many situations.
In conditions in which the child’s nutritional baseline is
excellent, such as in day care centers in the developed world,
asymptomatic carriers may not always need therapy (5, 121,
195, 203, 221, 237). However, it should be noted, that aymp-
tomatically infected children may excrete Giardia for months
(195), carry it home to family members and thus initiate infec-
tion in the household, and even help maintain high levels of
Giardia infection in a community (4, 196, 224; G. D. Overturf,
Editorial, Clin. Infect. Dis. 18:764–765, 1994). It is not uncom-
mon for a mother of a young child in day care to become
symptomatic with giardiasis, identifying the presence in the
household of Giardia which has been introduced by the asymp-
tomatic child. If there is recurrent diarrhea attributed to Gi-
ardia in day care which cannot be controlled by improved
122 GARDNER AND HILL CLIN.MICROBIOL.REV.
hygiene and by treatment and exclusion of children who are
symptomatic, consideration can be given to screening and
treating all the children in the day care setting (5, 18, 230).
If Giardia is detected in the stool and there is little likelihood
of reinfection, such as in a returned traveler, treatment can be
given. In the household, if one member is symptomatic and
there is the possibility that fecal-oral spread has occurred
within the family or that there is a common source of infection,
all family members should be screened and treated so that
reinfection will not occur.
Another factor to consider in deciding whether to treat
asymptomatic carriers is the consequences of transmission of
infection if the carrier is not treated, e.g., infection in food
handlers (169, 199). This group should be treated to prevent
food-borne outbreaks.
Resistance and relapse. Treatment failures have been re-
ported with all of the common anti-Giardia agents including
metronidazole, quinacrine, furazolidone, and albendazole.
However, it is important for the clinician faced with recurrence
of symptoms after therapy to differentiate between actual drug
resistance, cure followed by reinfection, and post-Giardia lac-
tose intolerance. Therefore, the first step is to document true,
persistent infection by sending a stool sample for O&P exam-
ination or Giardia antigen detection. If the sample is positive,
a careful exposure history should provide information about
the likelihood of reinfection, and reinfected individuals should
respond to the original therapeutic agent. Reinfection would
be common in regions of endemicity around the world and in
situations of poor fecal-oral hygiene. If a patient has become
reinfected, risk factors should be identified and the patient
should be counseled regarding proper hygiene and prevention
measures.
Post-Giardia lactose intolerance is the most common of the
disaccharidase deficiencies associated with giardiasis and may
occur in 20 to 40% of patients (65). Thus, if the stool is
negative for Giardia, a trial of avoiding lactose-containing
foods and liquids should be instituted. This syndrome may take
several weeks to resolve.
True treatment failure could mean infection with a drug-
resistant isolate of Giardia. Resistance to most anti-Giardia
agents has been documented or induced in vitro (29, 154,
245–247), and multiple, genotypically different clones of G.
lamblia with different drug class susceptibilities have been
found in the human duodenum (46, 81, 160, 248). However,
there has not been a consistent correlation between in vitro
resistance or sensitivity and clinical failure or success (43, 160,
164, 225, 249), still leaving open the question of true parasite
resistance.
Clinically resistant strains have been treated with longer
repeat courses or higher doses of the original agent (91, 165,
178). However, the most efficacious means of eradicating these
infections seems to involve using a drug from a different class
to avoid potential cross-resistance (52, 92). An initial switch to
a drug of a different class may not always be effective as dem-
onstrated in two French patients who failed albendazole treat-
ment following two courses of metronidazole but did respond
to quinacrine (P. Brasseur and L. Favennec, Letter, Parasite
2:422, 1995). Combination regimens using metronidazole-al-
bendazole, metronidazole-quinacrine, or other active drugs or
giving a nitroimidazole plus quinacrine for courses of at least 2
weeks have proven successful against refractory infection (44,
182a, 197, 225, 234). On occasion, several different combina-
tions or approaches will be necessary to effect cure.
In cases of giardiasis in which alternative therapy is not
effective, other possibilities should be considered, such as the
presence of immunologic deficiency. Chronic giardiasis in pa-
tients with hypogammaglobulinemia is well recorded (106, 108,
216) and can be difficult to treat, often requiring prolonged
courses of therapy. Although Giardia is seen in homosexual
men who engage in oral-anal sexual practices (162, 200, 226),
illness may often be neither severe nor prolonged (148). Nev-
ertheless, in AIDS patients with severe giardiasis, prolonged or
combination therapy may be necessary (182a).
RECOMMENDATIONS
An approach to the diagnosis and management of suspected
giardiasis is illustrated in Fig. 2 and discussed in more detail
above (see “Background”). If stools are negative, an empiric
course of therapy can be given; however, an alternative diag-
nosis should be considered. If there is no response to therapy
in stool-negative cases, invasive testing by endoscopy can be
performed to help determine the diagnosis, particularly if the
patient is immunocompromised.
When treatment is carried out, the agents of choice are
listed in Table 3 and the dosages are given in Table 2. The most
effective agents for therapy of giardiasis are single doses of
tinidazole or ornidazole, 5 to 7 days of quinacrine, and 5 to 7
days of metronidazole. Tinidazole and ornidazole are not ap-
proved or available in the United States. Production of quin-
acrine has been discontinued, but it still may be obtained on a
limited basis; however, it has significant side effects, particu-
larly in children. Therefore, the treatment of choice in the
United States for both adults and children is metronidazole. A
standard course of 5 to 7 days should effectively treat 90% or
more of infected individuals. Although the efficacy of 3 days of
2 to 2.4 g in a single daily dose approaches that of longer
regimens, this regimen is not recommended. The drug has not
TABLE 3. Recommendations for therapy of giardiasis
Clinical scenario Drug and duration of treatment
a
Symptomatic infection, USA
Adult and pediatric Metronidazole for 5–7 days
Alternatives Furazolidone for 7–10 days
or quinacrine for 5–7 days
or albendazole for 5–7 days
Symptomatic infection, overseas
Adult and pediatric Tinidazole (single dose) or
ornidazole (single dose)
Pregnancy
First trimester Paromomycin for 5–10 days
Second and third trimesters Paromomycin for 5–10 days
or metronidazole for 5–7
days
Resistant infection or relapse Drug of different class or
combination nitroimidazole
plus quinacrine for 2 wk or
more
a
For drug dosing, see Table 2.
VOL. 14, 2001 TREATMENT OF GIARDIASIS 123
received a Food and Drug Administration indication for giar-
diasis, and these high doses may have increased side effects.
Furazolidone is an effective alternative but requires 7 to 10
days of treatment four times a day, which will probably affect
compliance. Of the newer therapeutics, albendazole in a 5-day
regimen seems most promising, but additional studies are
needed. It has the advantage of having broad antiparasitic
effect, which may be beneficial in developing-world settings.
In pregnancy, if treatment is required, paromomycin should
be tried in the first trimester and paromomycin or metronida-
zole should be used in the second and third trimesters.
Treatment of all asymptomatic patients calls for careful in-
terpretation of the clinical situation, but they may not always
require therapy.
It can be expected that parasites will be cleared from the
stool in 3 to 5 days and that symptoms will resolve in 5 to 7 days
(91, 100, 131, 171). If the symptoms do not abate, the patient
should be evaluated for treatment failure or lactose intoler-
ance. If resistance or relapse has occurred, treatment with a
drug of a different class or with a combination of a nitroimid-
azole and quinacrine for at least 2 weeks should eradicate
infection.
ACKNOWLEDGMENT
We thank Theodore Nash for helpful comments and suggestions.
REFERENCES
1. Reference deleted.
2. Reference deleted.
3. Abdi, Y. A., L. L. Gustafsson, O. Ericsson, and U. Hellgren. 1995. Hand-
book of drugs for tropical parasitic infections, 2nd ed. p. 12–16. Taylor &
Francis Ltd., London, United Kingdom.
4. Addiss, D. G., J. P. Davis, J. M. Roberts, and E. E. Mast. 1992. Epidemi-
ology of giardiasis in Wisconsin: increasing incidence of reported cases and
unexplained seasonal trend. Am. J. Trop. Med. Hyg. 47:13–19.
5. Addiss, D. G., D. D. Juranek, and H. C. Spencer. 1991. Treatment of
children with asymptomatic and nondiarrheal Giardia infection. Pediatr.
Infect. Dis. J. 10:843–846.
6. Agarwal, A. K., M. Singh, M. Gupta, R. Saxena, A. Puri, A. K. Verma, R. P.
Saxena, C. B. Dubey, and K. C. Saxena. 1994. Management of giardiasis by
an immuno-modulatory herbal drug Pippali rasayana. J. Ethnopharmacol.
44:143–146.
7. Aldeen, W. E., K. Carroll, A. Robison, M. Morrison, and D. Hale. 1998.
Comparison of nine commercially available enzyme-linked immunosorbent
assays for the detection of Giardia lamblia in fecal specimens. J. Clin.
Microbiol. 36:1338–1340.
8. Al-Waili, N. S., B. H. Al-Waili, and K. Y. Saloom. 1988. Therapeutic use of
mebendazole in giardial infections. Trans. R. Soc. Trop. Med. Hyg. 82:438.
9. Al-Waili, N. S. D., and N. U. Hasan.1992. Mebendazole in giardial infec-
tions: a comparative study with metronidazole. J. Infect. Dis. 165:1170–
1171.
10. American Academy of Pediatrics Committee on Drugs. 1994. The transfer
of drugs and other chemicals into human milk. Pediatrics 93:137–150.
11. Andersson, T., J. Forssell, and G. Sterner. 1972. Outbreak of giardiasis:
effect of a new antiflagellate drug, tinidazole. Br. Med. J. 2:449–451.
12. Andrews, B. J., and B. Bjorvatin. 1994. Chemotherapy of Entamoeba his-
tolytica: studies in vitro with bacitracin and its zinc salt. Trans. R. Soc. Trop.
Med. Hyg. 88:98–100.
13. Andrews, B. J., H. Mylvaganam, and A. Yule. 1994. In vitro sensitivity of
Trichomonas vaginalis, Tritrichomonas foetus and Giardia intestinalis to bac-
itracin and its zinc salt. Trans. R. Soc. Trop. Med. Hyg. 88:704–706.
14. Andrews, B. J., D. Panitescu, G. H. Jipa, A. C. Vasile-Bugarin, R. P. Vasiliu,
and J. R. Ronnevig. 1995. Chemotherapy for giardiasis: randomized clinical
trial of bacitracin, bacitracin zinc, and a combination of bacitracin zinc with
neomycin. Am. J. Trop. Med. Hyg. 52:318–321.
15. Awadalla, H. N., S. H. el-Gowhary, H. A. H. Sadaka, and A. M. Khalifa.
1995. Aminosidine sulphate in experimental giardiasis. J. Egypt. Soc. Para-
sitol. 25:53–61.
16. Bakshi, J. S., J. M. Ghiara, and A. S. Nanivadeker. 1978. How does
tinidazole compare with metronidazole? A summary of reports of Indian
trials in amoebiasis and giardiasis. Drugs 15:S31–S42.
17. Reference deleted.
18. Bartlett, A. V., S. J. Englender, B. A. Jarvis, L. Ludwig, J. F. Carlson, and
J. P. Topping. 1991. Controlled trial of Giardia lamblia: control strategies in
day care centers. Am. J. Public Health 81:1001–1006.
19. Bassily, S., Z. Farid, N. A. el Masry, and E. M. Mikhail. 1987. Treatment
of intestinal E. histolytica and G. lamblia with metronidazole, tinidazole,
and ornidazole: a comparative study. J. Trop. Med. Hyg. 90:9–12.
20. Bassily, S., Z. Farid, J. W. Mikhail, D. C. Kent, and J. S. Lehman. 1970.
The treatment of Giardia lamblia infection with mepacrine, metronidazole
and furazolidone. J. Trop. Med. Hyg. 73:15–18.
21. Baveja, U. K., V. N. Bhatia, and D. C. Warhurst. 1998. Giardia lamblia:
in-vitro sensitivity to some chemotherapeutic agents. J. Commun. Dis. 30:
79–84.
22. Bean, N. H., J. S. Goulding, C. Lao, and F. J. Angulo. 1996. Surveillance for
foodborne-disease outbreaks—United States, 1988–1992. CDC Surveil-
lance Summaries, October 25, 1996. Morb. Mortal. Wkly. Rep. 45(NSS-5):
1–66.
23. Beard, C. M., K. L. Noller, and W. M. O’Fallon. 1988. Cancer after expo-
sure to metronidazole. Mayo Clin. Proc. 63:147–153.
24. Beard, C. M., K. L. Noller, W. M. O’Fallon, L. T. Kurland, and M. B.
Dockerty. 1979. Lack of evidence for cancer due to use of metronidazole.
N. Engl. J. Med. 301:519–522.
25. Bell, C. A., M. Cory, T. A. Fairley, J. E. Hall, and R. R. Tidwell. 1991.
Structure-activity relationships of pentamidine analogs against Giardia lam-
blia and correlation of antigiardial activity with DNA-binding affinity. An-
timicrob. Agents Chemother. 35:1099–1107.
26. Berget, A., and T. Weber. 1972. Metronidazole and pregnancy. Ugeskr.
Laeg. 134:2085–2089.
27. Bingham, A. K., and E. A. Meyer. 1979. Giardia excystation can be induced
in vitro in acidic solutions. Nature (London). 277:301–302.
28. Black, R. E., A. C. Dykes, S. P. Sinclair, and J. G. Wells. 1977. Giardiasis
in day-care centers: evidence of person-to-person transmission. Pediatrics
60:486–491.
29. Boreham, P. F. L., R. E. Phillips, and R. W. Shepherd. 1988. Altered uptake
of metronidazole in vitro by stocks of Giardia intestinalis with different drug
sensitivities. Trans. R. Soc. Trop. Med. Hyg. 82:104–106.
30. Boreham, P. F. L., R. E. Phillips, and R. W. Shepherd. 1985. A comparison
of the in-vitro activity of some 5-nitroimidazoles and other compounds
against Giardia intestinalis. J. Antimicrob. Chemother. 16:589–595.
31. Boreham, P. F. L., R. E. Phillips, and R. W. Shepherd. 1987. Heterogeneity
in the responses of clones to Giardia intestinalis to anti-giardial drugs.
Trans. R. Soc. Trop. Med. Hyg. 81:406–407.
32. Boreham, P. F. L., R. E. Phillips, and R. W. Shepherd. 1984. The sensitivity
of Giardia intestinalis to drugs in vitro. J. Antimicrob. Chemother. 14:449–
461.
33. Boreham, P. F. L., and J. A. Upcroft. 1991. The activity of azithromycin
against stocks of Giardia intestinalis in vitro and in vivo. Trans. R. Soc. Trop.
Med. Hyg. 85:620–621.
34. Bost, R. G. 1977. Metronidazole: mammalian mutagenicity, p. 126–131.
Proceedings of the International Metronidazole Conference, Montreal,
Canada. Excerpta Medica, Amsterdam, The Netherlands.
35. Reference deleted.
36. Briggs, G. G., R. K. Freeman, and S. J. Yaffe. 1990. Metronidazole, p.
430–433. In G. G. Briggs, R. K. Freeman, and S. J. Yaffe (ed.), Drugs in
pregnancy and lactation, 3rd ed. The Williams & Wilkins Co., Baltimore,
Md.
37. Brodsky, R. E., H. C. Spencer, and M. G. Schultz. 1974. Giardiasis in
American travelers to the Soviet Union. J. Infect. Dis. 130:319–323.
38. Brown, D. M., J. A. Upcroft, and P. Upcroft. 1996. A H
2
O-producing
NADH oxidase from the protozoan parasite Giardia duodenalis. Eur.
J. Biochem. 241:155–161.
39. Bulut, B. U., S. B. Gulnar, and D. Aysev. 1996. Alternative treatment
protocols in giardiasis: a pilot study. Scand. J. Infect. Dis. 28:493–495.
40. Buret, A., N. denHollander, P. M. Wallis, D. Befus, and M. E. Olson. 1991.
Zoonotic potential of giardiasis in domestic ruminants. J. Infect. Dis. 162:
231–237.
41. Buret, A., D. G. Gall, P. N. Nation, and M. E. Olson. 1990. Intestinal
protozoa and epithelial kinetics, structure and function. Parasitol. Today
12:375–380.
42. Burtin, P., A. Taddio, O. Ariburnu, T. R. Einarson, and G. Koren. 1995.
Safety of metronidazole in pregnancy: a meta-analysis. Am. J. Obstet.
Gynecol. 172:525– 529.
43. Butcher, P. D., A. M. Cevallos, S. Carnaby, E. M. Alstead, E. T. Swarbrick,
and M. J. G. Farthing. 1994. Phenotypic and genotypic variation in Giardia
lamblia isolates during chronic infection. Gut 35:51–54.
44. Cacopardo, B., I. Patamia, V. Bonaccorso, O. Di Paola, S. Bonforte, and G.
Brancati. 1995. Efficacia sinergica dell’associazione albendazole-metron-
idazolo nella giardiasi refrattaria a monoterapia con metronidazolo. Clin.
Ter. 146:761–767.
45. Calzada, F., C. M. Cerda-Garcia-Rojas, M. Meckes, R. Cedillo-Rivera, R.
Bye, and R. Mata. 1999. Geranins A and B, new antiprotozoal A-type
proanthocyanidins from Geranium nivem. J. Nat. Prod. 62:705–709.
46. Carnaby, S., P. H. Ketelaris, A. Neem, and M. J. G. Farthing. 1994. Ge-
124 GARDNER AND HILL CLIN.MICROBIOL.REV.
notypic heterogeneity within Giardia lamblia isolates demonstrated by M13
DNA fingerprinting. Infect. Immun. 62:1875–1880.
47. Carter, C. H., A. Bayles, and P. E. Thompson. 1962. Effects of paromomycin
sulfate in man against Entamoeba histolytica and other intestinal protozoa.
Am. J. Trop. Med. Hyg. 11:448–451.
48. Cha´vez, B., L. Gonza´lez-Mariscal, R. Cedillo-Rivera, and A. Martı´nez-
Palomo. 1995. Giardia lamblia: in vitro cytopathic effect of human isolates.
Exp. Parasitol. 80:133–138.
49. Cimerman, B., H. Boruchovski, F. M. Cury, L. M. Bichued, and A. Ieri.
1989. A comparative study of secnidazole and metronidazole in the treat-
ment of giardiasis, p. 28–34. In N. Katz and A. T. Willis (ed.), Secnidazole:
a new approach in 5-nitroimidazole therapy. Proceedings from the 16th
International Congress of Chemotherapy. Excerpta Medica, Amsterdam,
The Netherlands.
50. Clark, D. P. 1999. New insights into human cryptosporidiosis. Clin. Micro-
biol. Rev. 12:554–563.
51. Clark, J. T., and D. V. Holberton. 1988. Triton-labile antigens in flagella
isolated from Giardia lamblia. Parasitol. Res.74:415–423.
52. Craft, J. C., T. Murphy, and J. D. Nelson. 1981. Furazolidone and quina-
crine. Comparative study of therapy for giardiasis in children. Am. J. Dis.
Child. 135:164–166.
53. Craun, G. F. 1986. Waterborne giardiasis in the United States 1965–1984.
Lancet ii:513–514.
54. Craun, G. F. 1996. Waterborne outbreaks of giardiasis: current status, p.
243–261. In S. L. Erlandsen and E. A. Meyer (ed.), Giardia and giardiasis:
biology, pathogenesis, and epidemiology. Plenum Press, New York, N.Y.
55. Crouch, A. A., W. K. Seow, and Y. H. Thong. 1986. Effect of twenty-three
chemotherapeutic agents on the adherence and growth of Giardia lamblia
in vitro. Trans. R. Soc. Trop. Med. Hyg. 80:893–896.
56. Crouch, A. A., W. K. Seow, L. M. Whitman, and Y. H. Thong. 1990.
Sensitivity in vitro of Giardia intestinalis to dyadic combinations of azithro-
mycin, doxycycline, mefloquine, tinidazole and furazolidone. Trans. R. Soc.
Trop. Med. Hyg. 84:246–248.
57. Darbon, A., A. Portal, L. Girier, J. Pantin, and C. Leclaire. 1962. Traite-
ment de la giardiase (lambliase) par le me´tronidazole. Presse Med. 70:15–
16.
58. Davidson, R. A. 1984. Issues in clinical parasitology: the treatment of
giardiasis. Am. J. Gastroenterol. 79:256–261.
59. deRegnier, D. P., L. Cole, D. G. Schupp, and S. L. Erlandsen. 1989. Via-
bility of Giardia cysts suspended in lake, river, and tap water. Appl. Envi-
ron. Microbiol. 55:1223–1229.
60. Reference deleted.
61. Djamiatun, K., and G. M. Faubert. 1998. Exogenous cytokines released by
spleen and Peyer’s patch cells removed from mice infected with Giardia
muris. Parasite Immunol. 20:27–36.
62. Dobell, C. 1920. The discovery of the intestinal protozoa of man. Proc. R.
Soc. Med. 13:1–15.
63. Dobo´n, J. F., A. E. Cedrato, and N. Martino de Colom. 11 July 1963. El uso
de la paromomicina en amebiasis y giardiasis intestinalis, p. 1012, El ´a
Me´dico, Buenos Aires, Argentina.
64. Doumbo, O., J. F. Rossignol, E. Pichard, H. A. Traore, M. Dembele, M.
Diakite, F. Traore, and D. A. Diallo. 1997. Nitazoxanide in the treatment of
cryptosporidial diarrhea and other intestinal parasitic infections associated
with acquired immunodeficiency syndrome in tropical Africa. Am. J. Trop.
Med. Hyg. 56:637– 639.
65. Duncombe, V. M., T. D. Bolin, A. E. Davis, and R. L. Crouch. 1978.
Histopathology in giardiasis: a correlation with diarrhea. Aust. N. Z. J.
Med. 8:392–396.
66. DuPont, H. L., and E. G. Capsuto. 1996. Persistent diarrhea in travelers.
Clin. Infect. Dis. 22:124–128.
67. Durel, P., V. Roiron, H. Siboulet, and L. J. Borel. 1960. Systemic treatment
of human trichomoniasis with a derivative of nitroimidazole. Br. J. Vener.
Dis. 36:21–26.
68. Dutta, A. K., M. A. Phadke, A. C. Bagade, V. Joshi, A. Gazder, T. K. Biswas,
H. H. Gill, and S. C. Jagota. 1994. A randomised multicentre study to
compare the safety and efficacy of albendazole and metronidazole in the
treatment of giardiasis in children. Indian J. Pediatr. 61:689–693.
69. Edlind, T. D. 1989. Susceptibility of Giardia lamblia to aminoglycoside
protein synthesis inhibitors: correlation with rRNA structure. Antimicrob.
Agents Chemother. 33:484–488.
70. Edlind, T. D. 1989. Tetracyclines as antiparasitic agents: lipophilic deriva-
tives are highly active against Giardia lamblia in vitro. Antimicrob. Agents
Chemother. 33:2144–2145.
71. Edlind, T. D., T. L. Hang, and P. R. Chakraborty. 1990. Activity of the
anthelminthic benzimidazoles against Giardia intestinalis in vitro. J. Infect.
Dis. 162:1408–1411.
72. Edwards, D. I. 1993. Nitroimidazole drugs—action and resistance mecha-
nisms. I. Mechanisms of action. J. Antimicrob. Chemother. 31:9–20.
73. Elliott, A. M., B. D. Klaus, D. S. North, and H. P. Martin. 1998. Furazo-
lidone-induced mood disorder during the treatment of refractory giardiasis
in a patient with AIDS. Clin. Infect. Dis. 26:1015.
74. Erlandsen, S., L. A. Sherlock, M. Januschka, D. G. Schupp, F. W. Schaefer
III, W. Jakubowski, and W. J. Bemrick. 1988. Cross-species transmission of
Giardia spp.: inoculation of beavers and muskrats with cysts of human,
beaver, mouse, and muskrat origin. Appl. Environ. Microbiol. 54:2777–
2785.
75. Erlandsen, S. L., P. T. Macechko, H. van Keulen, and E. L. Jarroll. 1996.
Formation of the Giardia cyst wall: studies on extracellular assembly using
immunogold labeling and high resolution field emission SEM. J. Eukaryot.
Microbiol. 43:416–429.
76. Erlich, J. H., R. F. Anders, I. C. Roberts-Thomson, J. W. Schrader, and
G. F. Mitchell. 1983. An examination of differences in serum antibody
specificities and hypersensitivity reactions as contributing factors to chronic
infection with the intestinal protozoan parasite, Giardia muris, in mice.
Aust. J. Exp. Biol. Med. Sci. 61:599–615.
77. Ey, P. L., T. Bruderer, C. Wehrli, and P. Kohler. 1996. Comparison of
genetic groups determined by molecular and immunological analyses of
Giardia isolated from animals and humans in Switzerland and Australia.
Parasitol. Res. 82:52–60.
78. Falagas, M. E., A. M. Walker, H. Jick, R. Ruthazer, J. Griffith, and D. R.
Snydman. 1998. Late incidence of cancer after metronidazole use: a
matched metronidazole user/nonuser study. Clin. Infect. Dis. 26:384–388.
79. Farbey, M. D., J. A. Reynoldson, and R. C. Thompson. 1995. In vitro drug
susceptibility of 29 isolates of Giardia intestinalis from humans as assessed
by an adhesion assay. Int. J. Parasitol. 25:593–599.
80. Reference deleted.
81. Farthing, M. J. G. 1992. Giardia comes of age: progress in epidemiology,
immunology and chemotherapy. J. Antimicrob. Chemother. 30:563–566.
82. Farthing, M. J. G. 1996. Giardiasis. Gastroenterol. Clin. North Am. 25:
493–515.
83. Farthing, M. J. G. 1997. The molecular pathogenesis of giardiasis. J. Pedi-
atr. Gastroenterol. Nutr. 24:79–88.
84. Farthing, M. J. G., and P. M. G. Inge. 1986. Antigiardial activity of the bile
salt-like solution antibiotic sodium fusidate. J. Antimicrob. Chemother.
17:165–171.
85. Farthing, M. J. G., P. M. G. Inge, and R. M. Pearson. 1987. Effect of
D-propranolol on growth and motility of flagellate protozoa. J. Antimicrob.
Chemother. 20:519–522.
86. Farthing, M. J. G., L. Mata, J. J. Urrutia, and R. A. Kronmal. 1986. Natural
history of Giardia infection of infants and children in rural Guatemala and
its impact on physical growth. Am. J. Clin. Nutr. 43:395–405.
87. Faubert, G. 2000. Immune response to Giardia duodenalis. Clin. Microbiol.
Rev. 13:35–54.
88. Reference deleted.
89. Garcia, L. S., and R. Y. Shimizu. 2000. Detection of Giardia lamblia and
Cryptosporidium parvum antigens in human fecal specimens using the Col-
orPac combination rapid solid-phase qualitative immunochromatographic
assay. J. Clin. Microbiol. 38:1267–1268.
90. Garcia, L. S., and R. Y. Shimizu. 1997. Evaluation of nine immunoassay kits
(enzyme immunoassay and direct fluorescence) for detection of Giardia
lamblia and Cryptosporidium parvum in human fecal specimens. J. Clin.
Microbiol. 35:1526–1529.
91. Garg, B. K. 1972. Furazolidone and metronidazole in the treatment of
giardiasis. Indian J. Pediatr. 39:264–266.
92. Gasco´n, J., R. Abo´s, M. E. Valls, and M. Coracha´n. 1990. Mebendazole and
metronidazole in giardial infections. Trans. R. Soc. Trop. Med. Hyg. 84:694.
93. Gazder, A. J., and M. Banerjee. 1978. Single dose therapy of giardiasis with
tinidazole and metronidazole. Drugs 15:S30–S32.
94. Gillin, F. D., and L. S. Diamond. 1981. Inhibition of clonal growth of
Giardia lamblia and Entamoeba histolytica by metronidazole, quinacrine
and other antimicrobial agents. J. Antimicrob. Chemother. 8:305–316.
95. Gillis, J. C., and L. R. Wiseman. 1996. Secnidazole. A review of its anti-
microbial activity, pharmacokinetic properties and therapeutic use in the
management of protozoal infections and bacterial vaginosis. Drugs 51:621–
638.
96. Gilman, R. H., E. Miranda, G. S. Marquis, M. Vestegui, and H. Martinez.
1988. Rapid reinfection by Giardia lamblia after treatment in a hyperen-
demic Third World community. Lancet i:343–345.
97. Goka, A. K. J., D. D. K. Rolston, V. I. Mathan, and M. J. G. Farthing. 1990.
The relative merits of faecal and duodenal juice microscopy in the diagnosis
of giardiasis. Trans. R. Soc. Trop. Med. Hyg. 84:66–67.
98. Goldman, P. 1980. Metronidazole. N. Engl. J. Med. 303:1212–1218.
99. Goodgame, R. W. 1996. Understanding intestinal spore-forming protozoa:
cryptosporidia, microsporidia, isospora, and cyclospora. Ann. Intern. Med.
124:429–441.
100. Gorbea Robles, M. C., J. G. Eternod, F. G. Vala´zquez, et al. 1989. Estudio
comparativo en amebiasis y giardiasis intestinal del lactante y pre-escolar:
eficacia y tolerancia del secnidazol vs metronidazol y etofamida. Investig.
Med. Int. 16:79–82.
101. Gordts, B., W. Hemelhof, C. Asselman, and J. P. Butzler. 1985. In vitro
susceptibilities of 25 Giardia lamblia isolates of human origin to six com-
monly used antiprotozoal agents. Antimicrob. Agents Chemother. 28:378–
380.
102. Reference deleted.
VOL. 14, 2001 TREATMENT OF GIARDIASIS 125
103. Gupta, M. C., and J. J. Urrutia. 1982. Effect of periodic antiascaris and
antigiardia treatment on nutritional status of preschool children. Am. J.
Clin. Nutr. 36:79–86.
104. Hall, A., and Q. Nahar. 1993. Albendazole as a treatment for infections
with Giardia duodenalis in children in Bangladesh. Trans. R. Soc. Trop.
Med. Hyg. 87:84–86.
105. Hartman, H. R., and F. A. Kyser. 1941. Giardiasis and its treatment. JAMA
116:2835–2839.
106. Hartong, W. A., W. K. Gourley, and C. Arvanitakis. 1979. Giardiasis: clin-
ical spectrum and functional-structural abnormalities of the small intestinal
mucosa. Gastroenterology 77:61–69.
107. Heinonen, O. P., D. Slone, and S. Shapiro. 1977. Birth defects and drugs in
pregnancy, p. 296–302. Publishing Sciences Group, Littleton, Mass.
108. Herzog, D., B. Hammer, J. Neuweiler, and E. Werder. 1998. Chronische
Giardiasis mit intestinalem Kleinwuchs and Pubertas tarda bei Immuno-
globulinmangelsyndrom: vollstandiges Aufholwachstum nach Therapie.
Schweiz. Med. Wochenschr. 128:623–628.
109. Hetsko, M. L., J. M. McCaffery, S. G. Svard, T. C. Meng, X. Que, and F. D.
Gillin. 1998. Cellular and transcriptional changes during excystation of
Giardia lamblia in vitro. Exp. Parasitol. 88:172–183.
110. Heyworth, M. F. 1992. Immunology of Giardia and Cryptosporidium infec-
tions. J. Infect. Dis. 166:465–472.
111. Hiatt, R. A., E. K. Markell, and E. Ng. 1995. How many stool examinations
are necessary to detect pathogenic intestinal protozoa? Am. J. Trop. Med.
Hyg. 53:36–39.
112. Hill, D. R. Giardia lamblia. In S. H. Gillespie and R. D. Pearson (ed.),
Principles and practice of clinical parasitology, in press. John Wiley & Sons,
Ltd., Chichester, England.
113. Hill, D. R. 1993. Giardiasis: Issues in management and treatment. Infect.
Dis. Clin. North Am. 7:503–525.
114. Hill, D. R., J. J. Burge, and R. D. Pearson. 1984. Susceptibility of Giardia
lamblia trophozoites to the lethal effect of human serum. J. Immunol.
132:2046–2052.
115. Hill, D. R., and T. E. Nash. 1999. Intestinal flagellate and ciliate infections,
p. 703–720. In R. L. Guerrant, D. H. Walker, and P. F. Weller (ed.),
Tropical infectious diseases. Principles, pathogens, & practice, vol. 1.
Churchill Livingstone, Philadelphia, Pa.
116. Hill, D. R., R. Pohl, and R. D. Pearson. 1986. Giardia lamblia: a culture
method for determining parasite viability. Am. J. Trop. Med. Hyg. 35:1129–
1133.
117. Inge, P. M. G., and M. J. G. Farthing. 1987. A radiometric assay for
antigiardial drugs. Trans. R. Soc. Trop. Med. Hyg. 81:345–347.
118. Isaac-Renton, J., J. Blatherwick, W. R. Bowie, M. Fyfe, M. Khan, A. Li, A.
King, M. McLean, L. Meed, W. Moorehead, C. S. Ong, and W. Robertson.
1999. Epidemic and endemic seroprevalence of antibodies to Cryptospo-
ridium and Giardia in residents of three communities with different drinking
water supplies. Am. J. Trop. Med. Hyg. 60:578–583.
119. Isaac-Renton, J. L., L. F. Lewis, C. S. Ong, and M. F. Nulsen. 1994. A
second community outbreak of waterborne giardiasis in Canada and sero-
logical investigation of patients. Trans. R. Soc. Trop. Med. Hyg. 88:395–
399.
120. Isaac-Renton, J. L., H. Shahriari, and W. R. Bowie. 1992. Comparison of an
in vitro method and an in vivo method of Giardia excystation. Appl. Envi-
ron. Microbiol. 58:1530–1533.
121. Ish-Horowicz, M., S. H. Korman, M. Shapiro, U. Har-Even, I. Tamir, N.
Strauss, and R. J. Deckelbaum. 1989. Asymptomatic giardiasis in children.
Pediatr. Infect. Dis. J. 8:773–779.
122. Jarroll, E. L., A. K. Bingham, and E. A. Meyer. 1981. Effect of chlorine on
Giardia lamblia cyst viability. Appl. Environ. Microbiol. 41:483–487.
123. Jephcott, A. E., N. T. Begg, and I. A. Baker. 1986. Outbreak of giardiasis
associated with mains water in the United Kingdom. Lancet i:730–732.
124. Johns, T., G. M. Faubert, J. O. Kokwaro, R. L. A. Mahunnah, and E. K.
Kimanani. 1995. Anti-giardial activity of gastrointestinal remedies of the
Luo of east Africa. J. Ethnopharmacol. 46:17–23.
125. Jokipii, A. M. M., M. Hemila¨, and L. Jokipii. 1985. Prospective study of
acquisition of cryptosporidium, Giardia lamblia, and gastrointestinal illness.
Lancet ii:487–489.
126. Jokipii, A. M. M., and L. Jokipii. 1978. Comparative evaluation of two
dosages of tinidazole in the treatment of giardiasis. Am. J. Trop. Med. Hyg.
27:758–761.
127. Jokipii, L., and A. M. M. Jokipii. 1978. Comparison of four dosage sched-
ules in the treatment of giardiasis with metronidazole. Infection. 6:92–94.
128. Jokipii, L., and A. M. M. Jokipii. 1974. Giardiasis in travelers: a prospective
study. J. Infect. Dis. 130:295–299.
129. Jokipii, L., and A. M. M. Jokipii. 1980. In vitro susceptibility of Giardia
lamblia to metronidazole and tinidazole. J. Infect. Dis. 141:317–325.
130. Jokipii, L., and A. M. M. Jokipii. 1979. Single-dose metronidazole and
tinidazole as therapy for giardiasis: success rates, side effects, and drug
absorption and elimination. J. Infect. Dis. 140:984–988.
131. Jokipii, L., and A. M. M. Jokipii. 1982. Treatment of giardiasis: compara-
tive evaluation of ornidazole and tinidazole as a single oral dose. Gastro-
enterology 83:399–404.
132. Kalyci, A. G., F. Cetinbkaya, M. Gunaydin, and N. Gurses. 1995. Compar-
ison of mebendazole with metronidazole and furazolidone in the treatment
of giardiasis in children. Ann. Saudi Med. 15:655–656.
133. Kang, E. W., K. Clinch, R. H. Furneaux, J. E. Harvey, P. J. Schofield, and
A. M. Gero. 1998. A novel and simple colorimetric method for screening
Giardia intestinalis and anti-giardial activity in vitro. Parasitology 117:229–
234.
134. Kaucner, C., and T. Stinear. 1998. Sensitive and rapid detection of viable
Giardia cysts and Cryptosporidium parvum oocysts in large-volume water
samples with wound fiberglass cartridge filters and reverse transcription-
PCR. Appl. Environ. Microbiol. 64:1743–1749.
135. Kavousi, S. 1979. Giardiasis in infancy and childhood: a prospective study
of 160 cases with comparison of quinacrine (Atabrine®) and metronidazole
(Flagyl®). Am. J. Trop. Med. Hyg. 28:19–23.
136. Kettis, A. A., and L. G. Magnius. 1973. Giardia lamblia infection in a group
of students after a visit to Leningrad in March 1970. Scand. J. Infect. Dis.
5:289–292.
137. Kollaritsch, H., E. Jeschko, and G. Wiederman. 1993. Albendazole is highly
effective against cutaneous larva migrans but not against Giardia infection:
results of an open pilot trial in travellers returning from the tropics. Trans.
R. Soc. Trop. Med. Hyg. 87:689.
138. Korman, S. H., E. Hais, and D. T. Spira. 1990. Routine in vitro cultivation
of Giardia lamblia by using the string test. J. Clin. Microbiol. 28:368–369.
139. Kramer, M. H., B. L. Herwaldt, G. F. Craun, R. L. Calderon, and D. D.
Juranek. 1996. Surveillance for waterborne-disease outbreaks—United
States, 1993–1994. CDC Surveillance Summaries, April 12, 1996. Morb.
Mortal. Weekly Rep. 45(SS-1):1–30.
140. Kreutner, A. K., V. E. Del Bene, and M. S. Amstey. 1981. Giardiasis in
pregnancy. Am. J. Obstet. Gynecol. 140:895–901.
141. Kucers, A., S. M. Crowe, M. L. Grayson, and J. F. Hoy. 1997. Bacitracin and
gramicidin, p. 542–543. In A. Kucers, S. M. Crowe, M. L. Grayson, and J. F.
Hoy (ed.), The use of antibiotics. A clinical review of antibacterial, anti-
fungal, and antiviral drugs, 5th ed. Butterworth-Heinemann, Oxford,
United Kingdom.
142. Kucers, A., S. M. Crowe, M. L. Grayson, and J. F. Hoy. 1997. Neomycin,
framycetin and paromomycin, p. 533–541. In A. Kucers, S. M. Crowe, M. L.
Grayson, and J. F. Hoy (ed.), The use of antibiotics. A clinical review of
antibacterial, antifungal, and antiviral Drugs, 5th ed. Butterworth-Heine-
mann, Oxford, United Kingdom.
143. Kucers, A., S. M. Crowe, M. L. Grayson, and J. F. Hoy. 1997. Nitrofurans:
nitrofurozone, furazolidone and nitrofurantoin, p. 922–923. In A. Kucers,
S. M. Crowe, M. L. Grayson, and J. F. Hoy (ed.), The use of antibiotics. A
clinical review of antibacterial, antifungal, and antiviral drugs, 5th ed. But-
terworth-Heinemann, Oxford, United Kingdom.
144. Kusumi, R. K., J. F. Plouffe, R. H. Wyatt, and R. J. Fass. 1980. Central
nervous system toxicity associated with metronidazole therapy. Ann. Intern.
Med. 93:59–60.
145. Kuzmicki, R., and J. Jeske. 1994. Observations of the efficacy of ornidazole
(Tiberal La Roche) in treatment of giardiasis. Wiad. Parazytol. 40:65–68.
146. Kyro¨nseppa¨, H., and T. Pettersson. 1981. Treatment of giardiasis: relative
efficacy of metronidazole as compared with tinidazole. Scand. J. Infect. Dis.
13:311–312.
147. Lau, A. H., N. P. Lam, S. C. Piscitelli, L. Wilkes, and L. H. Danzinger. 1992.
Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-
infectives. Clin. Pharmacokinet. 23:328–364.
148. Laughon, B. E., D. A. Druckman, A. Vernon, T. C. Quinn, B. F. Polk, J. F.
Modlin, R. H. Yolken, and J. G. Bartlett. 1988. Prevalence of enteric
pathogens in homosexual men with and without acquired immunodefi-
ciency syndrome. Gastroenterology 94:984–993.
149. Lengerich, E. J., D. G. Addiss, and D. D. Juranek. 1994. Severe giardiasis
in the United States. Clin. Infect. Dis. 18:760–763.
150. Lerman, S. J., and R. A. Walker. 1982. Treatment of giardiasis. Literature
review and recommendations. Clin. Pediatr. 21:409–414.
151. Levi, G. C., C. A. de Avila, and V. A. Neto. 1977. Efficacy of various drugs
for treatment of giardiasis. A comparative study. Am. J. Trop. Med. Hyg.
26:564–565.
152. Levine, W. C., J. F. Smart, D. L. Archer, N. H. Bean, and R. V. Tauxe. 1991.
Foodborne disease outbreaks in nursing homes, 1975 through 1987. JAMA
266:2105–2109.
153. Lindmark, D. G., and M. Muller. 1976. Antitrichomonad action, mutage-
nicity, and reduction of metronidazole and other nitroimidazoles. Antimi-
crob. Agents Chemother. 10:476–482.
154. Lindquist, H. D. 1996. Induction of albendazole resistance in Giardia lam-
blia. Microb. Drug Resist. 2:433–434.
155. Liu, L. X., and P. F. Weller. 1996. Antiparasitic drugs. N. Engl. J. Med.
334:1178–1184.
156. Lujan, H. D., M. R. Mowatt, and T. E. Nash. 1997. Mechanisms of Giardia
lamblia differentiation into cysts. Microbiol. Mol. Biol. Rev. 61:294–304.
157. MacDonald, T. T., and J. Spencer. 1988. Evidence that activated mucosal T
cells play a role in the pathogenesis of enteropathy in human small intes-
tine. J. Exp. Med. 167:1341–1349.
158. Mahbubani, M. H., F. W. I. Schaefer, D. D. Jones, and A. K. Bej. 1998.
126 GARDNER AND HILL CLIN.MICROBIOL.REV.
Detection of Giardia in environmental waters by immuno-PCR amplifica-
tion methods. Curr. Microbiol. 36:107–113.
159. Mahmud, M. A., C. Chappell, M. M. Hossain, M. Habib, and H. L. DuPont.
1995. Risk factors for development of first symptomatic Giardia infection
among infants of a birth cohort in rural Egypt. Am. J. Trop. Med. Hyg.
53:84–88.
160. Majewska, A. C., W. Kasprzak, J. F. De Jonckheere, and E. Kaczmarek.
1991. Heterogeneity in the sensitivity of stocks and clones of Giardia to
metronidazole and ornidazole. Trans. R. Soc. Trop. Med. Hyg. 85:67–69.
161. Mank, T. G., J. O. Zaat, A. M. Deelder, J. T. van Eijk, and A. M. Polder-
man. 1997. Sensitivity of microscopy versus enzyme immunoassay in the
laboratory diagnosis of giardiasis. Eur. J. Clin. Microbiol. Infect. Dis. 16:
615–619.
162. Markell, E. K., R. F. Havens, R. A. Kuritsubo, and J. Wingerd. 1984.
Intestinal protozoa in homosexual men of the San Francisco Bay area:
prevalence and correlates of infection. Am. J. Trop. Med. Hyg. 33:239–245.
163. Mata, L. J. 1978. The children of Santa Marı´a Cauque´: a prospective field
study of health and growth. MIT Press, Cambridge, Mass.
164. McIntyre, P., P. F. L. Boreham, R. E. Phillips, and R. W. Shepard. 1986.
Chemotherapy in giardiasis: clinical responses and in vitro drug sensitivity
of human isolates in axenic culture. J. Pediatr. 108:1005–1010.
164a.Medical Economics Company, Inc. 1999. Flagyl, p. 2961–2963. In Physi-
cians’ desk reference, 53rd ed. Medical Economics Co., Inc., Montvale, N.J.
164b.Medical Economics Company, Inc. 1999. Furoxone, p. 2627. In Physicians’
desk reference, 53rd ed. Medical Econimics Co., Inc., Montvale, N.J.
165. Meingasser, J. G., and P. G. Heyworth. 1981. Intestinal and urogenital
flagellates. Antibiotics Chemother. 30:163–202.
166. Meloni, B. P., R. C. A. Thompson, J. A. Reynoldson, and P. Seville. 1990.
Albendazole: a more effective antigiardial agent in vitro than metronidazole
or tinidazole. Trans. R. Soc. Trop. Med. Hyg. 84:375–379.
167. Meyer, E. A., and S. Radulescu. 1979. Giardia and giardiasis. Adv. Parasitol.
17:1–47.
168. Meyers, J. D., H. A. Kuharic, and K. K. Holmes. 1977. Giardia lamblia
infection in homosexual men. Br. J. Vener. Dis. 53:54–55.
169. Mintz, E. D., M. Hudson-Wragg, P. Mshar, M. L. Cartter, and J. L. Hadler.
1993. Foodborne giardiasis in a corporate office setting. J. Infect. Dis.
167:250–253.
170. Miotti, P. G., R. H. Gilman, M. Santosham, R. W. Ryder, and R. H. Yolken.
1986. Age-related rate of seropositivity of antibody to Giardia lamblia in
four diverse populations. J. Clin. Microbiol. 24:972–975.
171. Misra, P. K., A. Kumar, V. Agarwal, and S. C. Jagota. 1995. A comparative
trial of albendazole versus metronidazole in children with giardiasis. Indian
Pediatr. 32:779–782.
172. Miyares, C., I. Hollands, C. Castaneda, T. Gonzalez, T. Fragaso, R. Curras,
and C. Soria. 1988. Ensayo terapeutica con un preparado a base de pro-
poleo “propolisina” en la giardiasis del humano. Acta Gastroenterol. Lati-
noam. 18:195–201.
173. Monis, P. T., G. Mayrhofer, R. H. Andrews, W. L. Homan, L. Limper, and
P. L. Ey. 1996. Molecular genetic analysis of Giardia intestinalis isolates at
the glutamate dehydrogenase locus. Parasitology 112:1–12.
174. Moore, G. T., W. M. Cross, D. McGuire, C. S. Mollohan, N. N. Gleason,
G. R. Healy, and L. H. Newton. 1969. Epidemic giardiasis at a ski resort.
N. Engl. J. Med. 281:402–407.
175. Morgan, U. M., J. A. Reynoldson, and R. C. Thompson. 1993. Activities of
several benzimidazoles and tubulin inhibitors against Giardia spp. in vitro.
Antimicrob. Agents Chemother. 37:328–331.
176. Morrow, A. L., R. R. Reves, M. S. West, M. L. Guerrero, G. M. Ruiz-
Palacios, and L. K. Pickering. 1992. Protection against infection with Gi-
ardia lamblia by breast feeding in a cohort of Mexican infants. J. Pediatr.
121:363–370.
177. Muller, M. 1983. Mode of action of metronidazole on anaerobic bacteria
and protozoa. Surgery 93:165–171.
178. Murphy, T. V., and J. D. Nelson. 1983. Five vs. ten days’ therapy with
furazolidone for giardiasis. Am. J. Dis. Child. 137:267–270.
179. Namgung, R., J. S. Ryu, K. T. Lee, and C. T. Soh. 1985. The effect of
metronidazole and quinacrine on the morphology and the excystation of
Giardia lamblia. Yonsei Rep. Trop. Med. 16:28–44.
180. Nash, T., and W. G. Rice. 1998. Efficacies of zinc-finger-active drugs against
Giardia lamblia. Antimicrob. Agents Chemother. 42:1488–1492.
181. Nash, T. E. 1997. Antigenic variation in Giardia lamblia and the host’s
immune response. Philos. Trans. R. Soc. London Ser. B. 352:1369–1375.
182. Nash, T. E., D. A. Herrington, G. A. Losonsky, and M. M. Levine. 1987.
Experimental human infections with Giardia lamblia. J. Infect. Dis. 156:
974–984.
182a.Nash, T. E., C. A. Ohl, E. Thomas, G. Subramanian, P. Keiser, and T.
Moore. Treatment of refractory giardiasis. Clin. Infect. Dis., in press.
183. Nayak, N., N. K. Ganguly, B. N. S. Walia, V. Wahi, S. S. Kanwar, and R. C.
Mahajan. 1987. Specific secretory IgA in the milk of Giardia lamblia-
infected and uninfected women. J. Infect. Dis. 155:724–727.
184. Notis, W. M. 1972. Giardiasis and vitamin B12 malabsorption. Gastroen-
terology 63:1085.
185. Oberhuber, G., N. Kastner, and M. Stolte. 1997. Giardiasis: a histologic
analysis of 567 cases. Scand. J. Infect. Dis. 32:48–51.
186. Oren, B., E. Schgurensky, M. Ephros, I. Tamir, and R. Raz. 1991. Single-
dose ornidazole versus seven-day metronidazole therapy of giardiasis in
Kibbutzim children in Israel. Eur. J. Clin. Microbiol. Infect. Dis. 10:963–
965.
187. Osterholm, M. T., J. C. Forfang, T. L. Ristinen, A. G. Dean, J. W. Wash-
burn, J. R. Godes, R. A. Rude, and J. G. McCullough. 1981. An outbreak of
foodborne giardiasis. N. Engl. J. Med. 304:24–28.
188. Reference deleted.
189. Paget, T. A., E. L. Jarroll, P. Manning, D. G. Lindmark, and D. Lloyd. 1989.
Respiration in the cysts and trophozoites of Giardia muris. J. Gen. Micro-
biol. 135:145–154.
190. Paintlia, A. S., S. Descoteaux, B. Spencer, A. Chakraborti, N. K. Ganguly,
R. C. Mahajan, and J. Samuelson. 1998. Giardia lamblia groups A and B
among young adults in India. Clin. Infect. Dis. 26:190–191.
191. Palomino, H., C. Pe´rez, R. Donckaster, J. Sapunar, M. Gabor, A. Atı´as, V.
Parodi, and L. Narbona. 1970. Ensayo terape´utico con cinco medicamentos
en lambliasis. Bol. Chil. Parasitol. 25:52–56.
192. Pearce, D. A., J. A. Reynoldson, and R. C. Thompson. 1996. A comparison
of two methods for assessing drug sensitivity in Giardia duodenalis. Appl.
Parasitol. 37:111–116.
193. Pengsaa, K., C. Sirivichayakul, C. Pojjaroen-anant, S. Nimnual, and P.
Wisetsing. 1999. Albendazole treatment of Giardia intestinalis infections in
school children. S. Asian J. Trop. Med. Public Health 30:78–83.
194. Reference deleted.
195. Pickering, L. K., W. E. Woodward, H. L. DuPont, and P. Sullivan. 1984.
Occurrence of Giardia lamblia in children in day care centers. J. Pediatr.
104:522–526.
196. Polis, M. A., C. U. Tuazon, D. W. Alling, and E. Talamis. 1986. Transmis-
sion of Giardia lamblia from a day care center to the community. Am. J.
Public Health 76:1142–1144.
197. Popovic, O. S., and V. Milovic. 1990. Propranolol and metronidazole for the
treatment of metronidazole-resistant giardiasis. J. Clin. Gastroenterol. 12:
604–605.
198. Pungpak, S., V. Singhasivanon, D. Bunnag, B. Radomyos, P. Nibaddha-
sopon, and K. T. Harinasuta. 1996. Albendazole as a treatment for Giardia
infection. Ann. Trop. Med. Parasitol. 90:563–565.
199. Quick, R., K. Paugh, D. Addiss, J. Kobayashi, and R. Baron. 1992. Res-
taurant-associated outbreak of giardiasis. J. Infect. Dis. 166:673–676.
200. Quinn, T. C., W. E. Stamm, S. E. Goodell, E. Mkrtichian, J. Benedetti, L.
Corey, M. D. Schuffler, and K. K. Holmes. 1983. The polymicrobial origin
of intestinal infections in homosexual men. N. Engl. J. Med. 309:576–582.
201. Quiros-Buelna, E. 1989. Furazolidone and metronidazole for treatment of
giardiasis in children. Scand. J. Gastroenterol. 169:S65–S69.
202. Reference deleted.
203. Rauch, A. M., V. M. T. Rory, A. V. Bartlett, and L. K. Pickering. 1990.
Longitudinal study of Giardia lamblia infection in a day care center popu-
lation. Pediatr. Infect. Dis. J. 9:186–189.
204. Reiner, D. S., C. S. Wang, and F. D. Gillin. 1986. Human milk kills Giardia
lamblia by generating toxic lipolytic products. J. Infect. Dis. 154:825–832.
205. Reinthaler, F. F., G. Feierl, D. Stunzner, and E. Marth. 1998. Diarrhea in
returning Austrian tourists: epidemiology, etiology, and cost-analysis. J.
Travel Med. 5:65–72.
206. Rendtorff, R. C. 1954. The experimental transmission of human intestinal
protozoan parasites. II. Giardia lamblia cysts given in capsules. Am. J. Hyg.
59:209–220.
207. Reynoldson, J. A., J. M. Behnke, M. Gracey, R. J. Horton, R. Spargo, R. M.
Hopkins, C. C. Constantine, F. Gilbert, C. Stead, R. P. Hobbs, and R. C.
Thompson. 1998. Efficacy of albendazole against Giardia and hookworm in
a remote Aboriginal community in the north of Western Australia. Acta
Trop. 71:27–44.
208. Reynoldson, J. A., R. C. A. Thompson, and R. J. Horton. 1992. Albendazole
as a future antigiardial agent. Parasitol. Today 8:412–414.
209. Reynoldson, J. A., R. C. A. Thompson, and B. P. Meloni. 1991. The mode
of action of benzimidazoles against Giardia and their chemotherapeutic
potential against Giardia and other parasitic protozoa, p. 587–593. In G. H.
Coombs and M. J. North (ed.), Biochemical protozoology. Taylor & Francis
Ltd., London, United Kingdom.
210. Rice, E. W., and F. W. Schaefer. 1981. Improved in vitro excystation pro-
cedure for Giardia lamblia cysts. J. Clin. Microbiol. 14:709–710.
211. Rodriguez-Garcia, R., L. M. Rodriguez-Guzman, and A. H. Cruz del
Castillo. 1999. Eficacia y seguridad de mebendazol contra nitazoxanida en
el tratamiento de Giardia lamblia en nin˜os. Rev. Gastroenterol. Mex. 64:
122–126.
212. Roe, F. J. C. 1985. Safety of nitroimidazoles. Scand. J. Infect. Dis. 46:72–81.
213. Romero Cabello, R., L. R. Guerrero, M. R. Mun˜o´z Garcı´a, and A. Geyne
Cruz. 1997. Nitazoxanide for the treatment of intestinal protozoan and
helminthic infections in Mexico. Trans. R. Soc. Trop. Med. Hyg. 91:701–
703.
214. Romero-Cabello, R., L. Robert, R. Mun˜oz-Garcia, and J. Tanaka. 1995.
Estudio aleatorio para comparar seguridad y eficacia de albendazol y met-
VOL. 14, 2001 TREATMENT OF GIARDIASIS 127
ronidazol en el tratamiento de giardiasis en nin˜os. Rev. Latinoam. Micro-
biol. 37:315–323.
215. Rosa, F. W., C. Baum, and M. Shaw. 1987. Pregnancy outcomes after
first-trimester vaginitis drug therapy. Obstet. Gynecol. 69:751–755.
216. Rosen, F. S., M. D. Cooper, and R. J. P. Wedgwood. 1995. The primary
immunodeficiencies. N. Engl. J. Med. 333:431–440.
217. Rossignol, J. F., H. Maisonneuve, and Y. W. Cho. 1984. Nitroimidazoles in
the treatment of trichomoniasis, giardiasis, and amebiasis. Int. J. Clin.
Pharmacol. Ther. Toxicol. 22:63–72.
218. Rotblatt, M. D. 1983. Giardiasis and amebiasis in pregnancy. Drug Intell.
Clin. Pharm. 17:187–188.
219. Rousham, E. K. 1994. An increase in Giardia duodenalis infection among
children receiving periodic anthelminthic treatment in Bangladesh. J. Trop.
Pediatr. 40:329–333.
220. Sabchareon, A., T. Chongsuphajaisiddhi, and P. Attanath. 1980. Treatment
of giardiasis in children with quinacrine, metronidazole, tinidazole and
ornidazole. S. Asian J. Trop. Med. Public Health 11:280–284.
221. Sagi, E. F., M. Shapiro, and R. J. Deckelbaum. 1983. Giardia lamblia:
prevalence, influence on growth, and symptomatology in healthy nursery
children. Isr. J. Med. Sci. 19:815–817.
222. Salih, S. Y., and R. E. Abdalla. 1977. Symptomatic giardiasis in Sudanese
adults and its treatment with tinidazole. J. Trop. Med. Hyg. 80:11–13.
223. Samuelson, J. 1999. Why metronidazole is active against both bacteria and
parasites. Antimicrob. Agents Chemother. 43:1533–1541.
224. Sealy, D. P., and S. H. Schuman. 1983. Endemic giardiasis and day care.
Pediatrics 72:154–158.
225. Smith, P. D., F. D. Gillin, W. M. Spira, and T. E. Nash. 1982. Chronic
giardiasis: studies on drug sensitivity, toxin production, and host immune
response. Gastroenterology 83:797–803.
226. Smith, P. D., T. C. Quinn, W. Strober, E. N. Janoff, and H. Masur. 1992.
Gasirointestinal infections in AIDS. Ann. Intern. Med. 116:63–77.
227. Solomons, N. W. 1982. Giardiasis: nutritional implications. Rev. Infect. Dis.
4:859–869.
228. Sousa, M. C., and J. Poiares-da-Silva. 1999. A new method for assessing
metronidazole susceptibility of Giardia lamblia trophozoites. Antimicrob.
Agents Chemother. 43:2939–2942.
229. Speelman, P. 1985. Single-dose tinidazole for the treatment of giardiasis.
Antimicrob. Agents Chemother. 27:227–229.
230. Steketee, R. W., S. Reid, T. Cheng, J. S. Stoebig, R. G. Harrington, and J. P.
Davis. 1989. Recurrent outbreaks of giardiasis in a child care center, Wis-
consin. Am. J. Public Health 79:485–490.
231. Sullivan, P. S., H. L. DuPont, R. R. Arafat, S. A. Thornton, B. J. Selwyn, M.
A. El Alamy, and A. M. Zaki. 1988. Illness and reservoirs associated with
Giardia lamblia infection in rural Egypt: the case against treatment in
developing world environments of high endemicity. Am. J. Epidemiol.
127:1272–1281.
232. Suntornpoch, V., and B. Chavalittamrong. 1981. Treatment of giardiasis in
children with tinidazole, ornidazole and metronidazole. S. Asian J. Trop.
Med. Public Health 12:231–235.
233. Takeuchi, T., S. Kobayashi, M. Tanabe, and T. Fujiwara. 1985. In vitro
inhibition of Giardia lamblia and Trichomonas vaginalis growth by bithionol,
dichlorophene, and hexachlorophene. Antimicrob. Agents Chemother. 27:
65–70.
234. Taylor, G. D., W. M. Wenman, and D. L. J. Tyrrell. 1987. Combined
metronidazole and quinacrine hydrochloride therapy for chronic giardiasis.
Can. Med. Assoc. J. 136:1179–1180.
235. Thiriat, L., F. Sidaner, and J. Schwartzbrod. 1998. Determination of Gi-
ardia cyst viability in environmental and faecal samples by immunofluores-
cence, fluorogenic dye staining and differential interference microscopy.
Lett. Appl. Microbiol. 26:237–242.
236. Thompson, R. C. A., J. A. Reynoldson, and A. H. Mendis. 1993. Giardia and
giardiasis. Adv. Parasitol. 32:71–160.
237. Thompson, S. C. 1994. Giardia lamblia in children and the child care
setting: a review of the literature. J. Paediatr. Child Health 30:202–209.
238. Townson, S. M., G. R. Hanson, J. A. Upcroft, and P. Upcroft. 1994. A
purified ferredoxin from Giardia duodenalis. Eur. J. Biochem. 220:439–446.
239. Townson, S. M., J. A. Upcroft, and P. Upcroft. 1996. Characterization and
purification of pyruvate:ferredoxin oxidoreductase from Giardia duodenalis.
Mol. Biochem. Parasitol. 79:183–193.
240. Tracy, J. W., and L. T. Webster. 1996. Drugs used in the chemotherapy of
protozoal infections, p. 987–1008. In J. G. Hardman and L. E. Limbird
(ed.), The pharmacological basis of therapeutics, 9th ed. McGraw-Hill
Book Co., New York, N.Y.
241. Tripathi, D. M., N. Gupta, V. Lakshmi, K. C. Saxena, and A. K. Agrawal.
1999. Antigiardial and immunostimulatory effect of Piper longum on giar-
diasis due to Giardia lamblia. Phytother. Res. 13:561–565.
242. Underdown, B. J., I. C. Roberts-Thomson, R. F. Anders, and G. F. Mitchell.
1981. Giardiasis in mice: studies on the characteristics of chronic infection
in C3H/He mice. J. Immunol. 126:669–672.
243. Upcroft, J., R. Mitchell, N. Chen, and P. Upcroft. 1996. Albendazole resis-
tance in Giardia is correlated with cytoskeletal changes but not with a
mutation at amino acid 200 in beta-tubulin. Microb. Drug Resist. 2:303–
308.
244. Upcroft, J., and P. Upcroft. 1998. My favorite cell: Giardia. Bioessays
20:256–263.
245. Upcroft, J. A., R. W. Campbell, K. Benkali, P. Upcroft, and P. Vanelle.
1999. Efficacy of new 5-nitroimidazoles against metronidazole-susceptible
and -resistant Giardia, Trichomonas, and Entamoeba spp. Antimicrob.
Agents Chemother. 43:73–76.
246. Upcroft, J. A., R. W. Campbell, and P. Upcroft. 1996. Quinacrine-resistant
Giardia duodenalis. Parasitology 112:309–313.
247. Upcroft, J. A., and P. Upcroft. 1993. Drug resistance and Giardia. Parasitol.
Today 9:187–190.
248. Upcroft, J. A., and P. Upcroft. 1994. Two distinct varieties of Giardia in a
mixed infection from a single human patient. J. Eukaryot. Microbiol. 41:
189–194.
249. Upcroft, J. A., P. Upcroft, and P. F. L. Boreham. 1990. Drug resistance in
Giardia intestinalis. Int. J. Parasitol. 20:489–496.
250. Venkatesan, P. 1998. Albendazole. J. Antimicrob. Chemother. 41:145–147.
251. Voogd, C. E. 1981. On the mutagenicity of nitroimidazoles. Mutag. Res.
86:243–277.
252. Ward, W., L. Alvarado, N. D. Rawlings, J. C. Engel, C. Franklin, and J. H.
McKerrow. 1997. A primitive enzyme for a primitive cell: the protease
required for excystation of Giardia. Cell 89:437–444.
253. Webster, B. H. 1960. Furazolidone in the treatment of giardiasis. Am. J.
Dig. Dis. 5:618–622.
254. Wolfe, M. S. 1979. Giardiasis. Pediatr. Clin. North. Am. 26:295–303.
255. Wolfe, M. S. 1975. Giardiasis. JAMA 233:1362–1365.
256. Wolfe, M. S. 1992. Giardiasis. Clin. Microbiol. Rev. 5:93–100.
257. Woo, P. K. 1984. Evidence for animal reservoirs and transmission of Giardia
infection between animal species, p. 341–364. In S. L. Erlandsen and E. A.
Meyer (ed.), Giardia and giardiasis. Plenum Press, New York, N.Y.
258. World Health Organization Informal Working Group on Echinococcosis.
1996. Guidelines for treatment of cystic and alveolar echinococcosis in
humans. Bull. W. H. O. 74:231–242.
259. Yardley, J. H., J. Takano, and T. R. Hendrix. 1964. Epithelial and other
mucosal lesions of the jejunum in giardiasis. Jejunal biopsy studies. Bull.
Johns Hopkins Hosp. 115:389–406.
260. Youssef, M. Y. M., M. M. Essa, H. A. H. Sadaka, M. M. Eissa, and A. M.
Rizk. 1996. Effect of ivermectin on combined intestinal protozoal infection
(giardiasis and cryptosporidiosis). J. Egypt. Soc. Parasitol. 26:543–553.
261. Zaat, J. O., T. G. Mank, and W. J. Assendelft. 1997. A systematic review on
the treatment of giardiasis. Trop. Med. Int. Health 2:63–82.
262. Zimmerman, S. K., and C. A. Needham. 1995. Comparison of conventional
stool concentration and preserved-smear methods with Merifluor Crypto-
sporidium/Giardia Direct Immunofluorescence Assay and ProSpecT Giar-
dia EZ Microplate Assay for the detection of Giardia lamblia. J. Clin.
Microbiol. 33:1942–1943.
263. Ziv, G., and F. G. Sulman. 1974. Distribution of aminoglycoside antibiotics
in blood and milk. Res. Vet. Sci. 17:68–74.
128 GARDNER AND HILL CLIN.MICROBIOL.REV.
    • "This may be due to inadequate supplies and a shortage of health personnel, among other factors which provide adequate conditions for V. cholera O1, biotype El Tor, serotype Inaba to survive better in the warm environment and crowded areas which give better transmission from human to human by food and water since the El Tor strains have efficiency transmission from host to host when compared with classical cholera strains [56] [57]. diseases including cholera [71][73]. In the present study, 267 (4.7 %) enteric pathogens, including cholera and protozoa, were isolated out of 5698 diarrhea cases, while there have been 5431 (95.3%) negative cases. "
    [Show abstract] [Hide abstract] ABSTRACT: Vibrio cholera, causing acute watery diarrhea known as cholera disease, affects all ages and both genders. Cholera infection outbreaks in Iraq have been reported for several years. The recent cholera outbreak, emerged throughout 2015, was investigated using bacteriological laboratory tests, singleplex and multiplex PCR technique for the detection of V. cholera from stool samples. Furthermore the toxigenic potential coupled with the antibiotic susceptibility test for cholera and other bacteria were also investigated. The stool samples were collected from 5698 patients ad- mitted to Al-Yarmouk Teaching hospital and health care centers in Baghdad/Al-Karkh, Iraq, from the 1st of August to the 30th of December 2015. The V. cholera was isolated from 194 cases (3.4% of the cases age between 21 - 50 years). In addition, other enteric infections: Salmonellosis and Shi- gellosis 7 and 21 respectively, protozoan parasite Giardia lamblia and Entamoeba histolytica 2 and 43 cases respectively were also reported. High percentage of V. cholera infection was detected in October (122 cases, 62.8%), compared with other enteric infections that show high percentage of diarrheal disease in September and November. The results have confirmed that the cholera out- break was caused by V. cholera O1, biotype El Tor, and serotype Inaba. Seven virulence genes were identified ctxA, toxR, zot, ace, rfbO1, tcpA and ompW. Moreover, the cholera isolated strains were found sensitive to most antibiotic but resistant to nalidixic acid.
    Article · Aug 2016
    • "Chronic, neglected giardiasis without gastrointestinal complaints is an unusual cause of growth retardation. Extra-intestinal manifestations, failure to thrive and cognitive deficiencies have been reported as longterm sequelae of Giardia infections [4][5][6][7]. In our patient, documented partial GH deficiency was acquired as consequence of chronic small bowel inflammation and malabsorption and central hypothyroidism, all of which suggest pituitary dysfunction. "
    [Show abstract] [Hide abstract] ABSTRACT: Citation: Saranac L, Djuric Z, Stojsic Z, Milenovic A and Lazarevic D. Severe Growth Failure in a Prepubertal Boy: What is Behind the Scene?. Austin J Endocrinol Diabetes . 2016; 3(3): 1046. Austin J Endocrinol Diabetes - Volume 3 Issue 3 - 2016 ISSN : 2381-9200 | www.austinpublishinggroup.com Saranac et al. © All rights are reserved Austin Journal of Endocrinology and Diabetes Open Access Abstract Background: When examining a short child, the pediatrician-endocrinologist must be aware of the vast number of causative issues and the complex origin of growth disorders. Case Report: A prepubertal boy aged 12.75 years was referred for an endocrinological assessment because of severe growth retardation. His height of 119.5 cm was -4.8 SD for his Chronological Age (CA), his Height Age (HA) corresponded to 6.5 years, and his Body Mass (BM) of 21.4 kg was 0.6 kg below his ideal weight-for-height. The boy also presented very poor verbal skills and learning and hearing problems. He did not have any abdominal complaints, pain, nausea or abnormal stools; however, his appetite was poor. Results: Upper endoscopy revealed diffuse macro nodular changes in the distal duodenum. Because of this very unusual endoscopic picture, various polyposis syndromes and enteropathies were considered. However, the pathohistology of the small bowel biopsies revealed the real nature of the disease: the presence of Giardia lamblia trophozoites in the mucosa. Multihormonal acquired pituitary dysfunction was suspected and confirmed. Conclusion: We reported an unusual case of severe growth failure accompanied by poor cognitive, verbal and hearing skills caused by long- term giardiasis that probably began during a critical period for growth and development.
    Full-text · Article · Aug 2016 · Advances in Microbiology
    • "Chronic, neglected giardiasis without gastrointestinal complaints is an unusual cause of growth retardation. Extra-intestinal manifestations, failure to thrive and cognitive deficiencies have been reported as longterm sequelae of Giardia infections [4][5][6][7]. In our patient, documented partial GH deficiency was acquired as consequence of chronic small bowel inflammation and malabsorption and central hypothyroidism, all of which suggest pituitary dysfunction. "
    Full-text · Article · Aug 2016 · Advances in Microbiology
Show more